2. Anti-infection
  3. HIV
  4. Zidovudine

Zidovudine  (Synonyms: Azidothymidine; AZT; ZDV)

Cat. No.: HY-17413 Purity: 99.97%
COA
SDS
Handling Instructions Technical Support

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

For research use only. We do not sell to patients.

CAS No. : 30516-87-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Zidovudine:

Zidovudine Related Antibodies

Top Publications Citing Use of Products

    Zidovudine purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 May 12:2024.04.21.589969.

    Time-of-addition assay results for Zidovudine (1 μM; 2-12 h).

    Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050.  [Abstract]

    Zidovudine (AZT) (10 μM) efficiently inhibited HIV-1 infection showing 97% and 98% inhibition in TZM-bl cells and SupT1 cells, respectively.

    Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050.  [Abstract]

    SupT1 cells were evaluated for long-term cytotoxicity of Zidovudine (AZT) (10 μM; 30 d) treatment.

    Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050.  [Abstract]

    Zidovudine (AZT) (10 μM; 30 d) verified the inhibitory effect against HIV-1 replication in SupT1 cells over a prolonged treatment.

    View All HIV Isoform Specific Products:

    View All Isoforms
    HIV HIV-1 HIV-2

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

    IC50 & Target[1][2]

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    143B IC50
    12.25 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human 143B cells after 72 hrs by MTT assay
    Cytotoxicity against human 143B cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    143B IC50
    148.42 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
    Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    5637 IC50
    128.82 μM
    Compound: AZT
    Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 30108758]
    5637 IC50
    7 μM
    Compound: 1
    Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25811955]
    A549 IC50
    0.011 μM
    Compound: AZT
    Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
    Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
    		[PMID: 19537689]
    A549 IC50
    0.012 μM
    Compound: AZT
    Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
    Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
    		[PMID: 19537689]
    A549 IC50
    11.86 μM
    Compound: 3; AZT
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    A549 IC50
    16.19 μM
    Compound: 13, AZT
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    A549 IC50
    20.74 μM
    Compound: AZT
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    AA5 IC50
    0.0003 μM
    Compound: AZT
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    AA5 IC50
    0.0004 μM
    Compound: AZT
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    AA5 IC50
    0.006 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    AA5 IC50
    0.008 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    AA5 IC50
    0.009 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    AA5 IC50
    < 0.0003 μM
    Compound: AZT
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    AA5 IC50
    > 0.1 μM
    Compound: AZT
    Cytotoxicity against human AA5 cells by MTS assay
    Cytotoxicity against human AA5 cells by MTS assay
    		[PMID: 20086149]
    B(EBV+) EC50
    0.001 μM
    Compound: AZT
    Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
    Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
    		[PMID: 7932526]
    Bel-7402 EC50
    4.62 μM
    Compound: Zidovudine
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    		[PMID: 18313175]
    Bone marrow cell CC50
    0.5 μM
    Compound: ZDV, AZT
    Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
    Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
    		[PMID: 20439609]
    Bone marrow cell CC50
    0.89 μM
    Compound: ZDV, AZT
    Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
    Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
    		[PMID: 20439609]
    BxT EC50
    0.055 μM
    Compound: AZT
    Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
    Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
    		[PMID: 7932526]
    C3H CC50
    > 20 μM
    Compound: 3[AZT]
    Compound was evaluated cytotoxicity against moloney sarcoma virus (MSV) infected C3H cell cultures.
    Compound was evaluated cytotoxicity against moloney sarcoma virus (MSV) infected C3H cell cultures.
    		10.1016/0960-894X(96)00433-7
    C3H/3T3 EC50
    0.02 μM
    Compound: AZT
    Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
    Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
    		[PMID: 2016718]
    C3H/3T3 EC50
    > 100 μM
    Compound: AZT
    Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts
    Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts
    		[PMID: 10229629]
    C8166 CC50
    1139.47 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 20488700]
    C8166 CC50
    1145 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 20598530]
    C8166 CC50
    1400 μM
    Compound: AZT
    Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line
    Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line
    		10.1016/0960-894X(95)00257-T
    C8166 CC50
    200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 19685905]
    C8166 CC50
    3987.58 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 34812640]
    C8166 CC50
    4.07 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21534540]
    C8166 CC50
    4.07 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21650224]
    C8166 CC50
    4071.9 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 21561060]
    C8166 CC50
    4107.39 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 23046280]
    C8166 CC50
    4552.1 μM
    Compound: AZT
    Cytotoxicity against C8166 cells by MTT method
    Cytotoxicity against C8166 cells by MTT method
    		[PMID: 17291043]
    C8166 CC50
    4676.07 μM
    Compound: AZT; zidovudine
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    		[PMID: 27039251]
    C8166 CC50
    4690 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 26214125]
    C8166 CC50
    4913.8 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 23164656]
    C8166 CC50
    5041 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
    		[PMID: 21194939]
    C8166 CC50
    5091 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    		[PMID: 18396905]
    C8166 CC50
    5110 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 23099098]
    C8166 CC50
    5231.6 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
    		[PMID: 30596489]
    C8166 CC50
    5401.4 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT colorimetric assay
    Cytotoxicity against human C8166 cells by MTT colorimetric assay
    		[PMID: 21719299]
    C8166 CC50
    5401.4 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21788138]
    C8166 CC50
    5601.71 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 21689939]
    C8166 CC50
    5746.1 μM
    Compound: AZT
    Cytotoxicity against C8166 cells by MTT assay
    Cytotoxicity against C8166 cells by MTT assay
    		[PMID: 17315963]
    C8166 CC50
    5858.85 μM
    Compound: Zidovudine
    Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
    		[PMID: 27894873]
    C8166 CC50
    > 1 μM
    Compound: AZT
    Cytotoxicity against C8166 cells by MTT assay
    Cytotoxicity against C8166 cells by MTT assay
    		[PMID: 16279773]
    C8166 CC50
    > 1000 μM
    Compound: 1
    Concentration which reduces the viability of uninfected C8166 cells by 50%
    Concentration which reduces the viability of uninfected C8166 cells by 50%
    		10.1016/0960-894X(96)00446-5
    C8166 CC50
    > 1000 μM
    Compound: AZT
    Cytotoxicity in C8166 cell lines
    Cytotoxicity in C8166 cell lines
    		10.1016/0960-894X(96)00443-X
    C8166 CC50
    > 1000 μM
    Compound: AZT
    Concentration of compound required to reduce viability of C8166 cells by 50%.
    Concentration of compound required to reduce viability of C8166 cells by 50%.
    		10.1016/0960-894X(96)00444-1
    C8166 CC50
    > 1000 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 19413342]
    C8166 CC50
    > 100 μg/mL
    Compound: AZT
    Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
    Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
    		[PMID: 19515569]
    C8166 CC50
    > 200 μM
    Compound: AZT
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    Cytotoxicity against human C8166 cells after 3 days by MTT assay
    		[PMID: 23738539]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 16499331]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT method
    Cytotoxicity against human C8166 cells by MTT method
    		[PMID: 16643044]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against C8166 cells after 72 hrs by MTT method
    Cytotoxicity against C8166 cells after 72 hrs by MTT method
    		[PMID: 17489633]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT method
    Cytotoxicity against human C8166 cells by MTT method
    		[PMID: 18088099]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 20146529]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 23078294]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells by MTT assay
    Cytotoxicity against human C8166 cells by MTT assay
    		[PMID: 23327759]
    C8166 CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
    Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
    		[PMID: 23368966]
    C8166 CC50
    > 5.092 mM
    Compound: AZT
    Cytotoxicity in human C8166 cells
    Cytotoxicity in human C8166 cells
    		[PMID: 17574419]
    C8166 CC50
    > 500 μM
    Compound: AZT
    Ability to reduce 50% viability of C8166 cells acutely infected with HIV-2 strain IIIB
    Ability to reduce 50% viability of C8166 cells acutely infected with HIV-2 strain IIIB
    		[PMID: 8642557]
    C8166 CC50
    > 749 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human C8166 cells after 72 hrs by MTT method
    Cytotoxicity against human C8166 cells after 72 hrs by MTT method
    		[PMID: 18316190]
    C8166 EC50
    0.00152 μM
    Compound: AZT; zidovudine
    Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    		[PMID: 27039251]
    C8166 EC50
    0.0019 μM
    Compound: AZT
    Inhibition of HIV1-3B replication in C8166 cells
    Inhibition of HIV1-3B replication in C8166 cells
    		[PMID: 16279773]
    C8166 EC50
    0.0019 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    		[PMID: 19170521]
    C8166 EC50
    0.00324 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in C8166 cells assessed as inhibition of syncytia formation
    Antiviral activity against HIV1 3B infected in C8166 cells assessed as inhibition of syncytia formation
    		[PMID: 20488700]
    C8166 EC50
    0.0033 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 16643044]
    C8166 EC50
    0.0034 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect
    		[PMID: 16499331]
    C8166 EC50
    0.0034 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 in C8166 cells after 72 hrs
    Antiviral activity against HIV1 in C8166 cells after 72 hrs
    		[PMID: 18088099]
    C8166 EC50
    0.00436 μM
    Compound: AZT; zidovudine
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
    		[PMID: 27039251]
    C8166 EC50
    0.0043 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B in C8166 cells
    Antiviral activity against HIV1 3B in C8166 cells
    		[PMID: 17489633]
    C8166 EC50
    0.0045 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 19685905]
    C8166 EC50
    0.0045 μg/mL
    Compound: AZT
    Antiviral activity against HIV1-infected human C8166 cells
    Antiviral activity against HIV1-infected human C8166 cells
    		[PMID: 20146529]
    C8166 EC50
    0.004 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral replication
    		[PMID: 20598530]
    C8166 EC50
    0.006 μM
    Compound: AZT
    Effective dose to achieve 50% protection of C8166 cells acutely infected with HIV-2 strain IIIB
    Effective dose to achieve 50% protection of C8166 cells acutely infected with HIV-2 strain IIIB
    		[PMID: 8642557]
    C8166 EC50
    0.00794 μM
    Compound: AZT; zidovudine
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
    		[PMID: 27039251]
    C8166 EC50
    0.00812 μM
    Compound: AZT
    Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 21689939]
    C8166 EC50
    0.0087 μM
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
    Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
    		[PMID: 23046280]
    C8166 EC50
    0.0108 μM
    Compound: AZT
    Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
    Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
    		[PMID: 18396905]
    C8166 EC50
    0.011 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
    Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
    		[PMID: 18316190]
    C8166 EC50
    0.0128 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
    Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
    		[PMID: 21788138]
    C8166 EC50
    0.013 μM
    Compound: Zidovudine
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
    		[PMID: 27894873]
    C8166 EC50
    0.015 μM
    Compound: AZT
    Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells
    Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells
    		[PMID: 9154967]
    C8166 EC50
    0.016 μM
    Compound: 1
    Compound was evaluated for inhibitory activity against HIV-1 infected C8166 cells.
    Compound was evaluated for inhibitory activity against HIV-1 infected C8166 cells.
    		10.1016/0960-894X(96)00446-5
    C8166 EC50
    0.016 μM
    Compound: AZT
    Inhibitory activity against HIV-111B in C8166 cells
    Inhibitory activity against HIV-111B in C8166 cells
    		10.1016/0960-894X(95)00203-6
    C8166 EC50
    0.016 μM
    Compound: AZT
    Anti-HIV activity against HIV-1 infected C8166 cell lines
    Anti-HIV activity against HIV-1 infected C8166 cell lines
    		10.1016/0960-894X(96)00443-X
    C8166 EC50
    0.016 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity against HIV-1 infected C8166 cell lines
    Compound was evaluated for anti-HIV activity against HIV-1 infected C8166 cell lines
    		10.1016/0960-894X(96)00444-1
    C8166 EC50
    0.016 μM
    Compound: AZT
    Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
    Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
    		10.1016/S0960-894X(97)00022-X
    C8166 EC50
    0.016 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
    Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
    		[PMID: 11374977]
    C8166 EC50
    0.017 μM
    Compound: AZT
    Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
    Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
    		[PMID: 17291043]
    C8166 EC50
    0.019 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
    		[PMID: 23099098]
    C8166 EC50
    0.02 μM
    Compound: AZT
    In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.
    In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.
    		[PMID: 11020296]
    C8166 EC50
    0.02 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
    Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
    		[PMID: 24299567]
    C8166 EC50
    0.02 μM
    Compound: AZT
    Inhibition of p24 antigen formation in infected C8166-cells
    Inhibition of p24 antigen formation in infected C8166-cells
    		[PMID: 7504733]
    C8166 EC50
    0.0228 μM
    Compound: AZT
    Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 23164656]
    C8166 EC50
    0.023 μM
    Compound: AZT
    Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    		[PMID: 21719299]
    C8166 EC50
    0.023 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
    Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
    		[PMID: 21788138]
    C8166 EC50
    0.03 μM
    Compound: AZT
    Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
    Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
    		10.1016/0960-894X(95)00208-B
    C8166 EC50
    0.03 μM
    Compound: AZT
    Inhibition of syncytia formation in infected C8166-cells
    Inhibition of syncytia formation in infected C8166-cells
    		[PMID: 7504733]
    C8166 EC50
    0.03 μM
    Compound: AZT
    Inhibitory effects on HIV-1 induced syncytium formation in C8166 cells
    Inhibitory effects on HIV-1 induced syncytium formation in C8166 cells
    		[PMID: 8230098]
    C8166 EC50
    0.034 μM
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
    Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
    		[PMID: 23738539]
    C8166 EC50
    0.034 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23078294]
    C8166 EC50
    0.034 μg/mL
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
    Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
    		[PMID: 23368966]
    C8166 EC50
    0.04 μM
    Compound: AZT
    Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells.
    Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells.
    		10.1016/0960-894X(95)00585-H
    C8166 EC50
    0.1293 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 21689939]
    C8166 EC50
    0.4 μM
    Compound: AZT
    Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control C8166 cells
    Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control C8166 cells
    		[PMID: 11462972]
    C8166 EC50
    1.95 x 10-3 μM
    Compound: AZT
    Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 19413342]
    C8166 EC50
    10.59 nM
    Compound: AZT
    Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 21689939]
    C8166 EC50
    12.8 nM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 23164656]
    C8166 EC50
    12.82 nM
    Compound: AZT
    Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    		[PMID: 21719299]
    C8166 EC50
    39 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
    		[PMID: 21719299]
    C8166 EC50
    39 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
    		[PMID: 23164656]
    C8166 EC50
    4.5 x 10-3 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
    		[PMID: 21561060]
    C8166 EC50
    uM μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21534540]
    C8166 ED50
    0.01 μM
    Compound: 1a
    Compound was tested for its ability to inhibit the replication of HIV-1 in C8166 T-cells
    Compound was tested for its ability to inhibit the replication of HIV-1 in C8166 T-cells
    		10.1016/S0960-894X(00)80316-9
    C8166 IC50
    0.004 μM
    Compound: AZT
    Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
    Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
    		10.1016/0960-894X(95)00257-T
    C8166 IC50
    0.0085 μM
    Compound: 1
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    		[PMID: 2165161]
    C8166 IC50
    1565.72 μg/mL
    Compound: AZT
    Cytotoxicity against human C8166 cells assessed as reduction in cell viability
    Cytotoxicity against human C8166 cells assessed as reduction in cell viability
    		[PMID: 31401538]
    C8166 IC50
    > 100 μM
    Compound: AZT
    Concentration which results in 50% survival of uninfected untreated control C8166 cells (cytotoxicity of the compound)
    Concentration which results in 50% survival of uninfected untreated control C8166 cells (cytotoxicity of the compound)
    		[PMID: 11462972]
    CCRF-CEM CC50
    14 μM
    Compound: AZT
    Cytotoxicity against human CEM cell
    Cytotoxicity against human CEM cell
    		[PMID: 25458500]
    CCRF-CEM CC50
    14.3 mM
    Compound: AZT
    Cytotoxic concentration required to inhibit 50% of HIV-1 in CEM cells
    Cytotoxic concentration required to inhibit 50% of HIV-1 in CEM cells
    		[PMID: 9341906]
    CCRF-CEM CC50
    14.3 μM
    Compound: AZT
    Cytotoxic concentration towards CEM cells
    Cytotoxic concentration towards CEM cells
    		10.1016/0960-894X(95)00302-A
    CCRF-CEM CC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells
    Cytotoxicity against human CEM cells
    		[PMID: 23623492]
    CCRF-CEM CC50
    23.04 μM
    Compound: AZT
    Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
    Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
    		[PMID: 20598537]
    CCRF-CEM CC50
    24 μM
    Compound: AZT
    Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
    Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
    		[PMID: 20350812]
    CCRF-CEM CC50
    24.06 μM
    Compound: AZT
    Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
    Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
    		[PMID: 20137956]
    CCRF-CEM CC50
    24.06 μM
    Compound: AZT
    Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
    Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
    		[PMID: 21295891]
    CCRF-CEM CC50
    24.1 μM
    Compound: AZT
    Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
    Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
    		[PMID: 21227704]
    CCRF-CEM CC50
    35.6 μg/mL
    Compound: AZT
    compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
    compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
    		[PMID: 9548818]
    CCRF-CEM CC50
    500 μM
    Compound: AZT
    Cytotoxic concentration against HIV-1 infected CEM cell lines
    Cytotoxic concentration against HIV-1 infected CEM cell lines
    		[PMID: 7837220]
    CCRF-CEM CC50
    56.1 μM
    Compound: AZT
    Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    		[PMID: 26451771]
    CCRF-CEM CC50
    6 μM
    Compound: n AZT
    Concentration required to reduce the viability of mock-infected CEM cells by 50%
    Concentration required to reduce the viability of mock-infected CEM cells by 50%
    		[PMID: 11714616]
    CCRF-CEM CC50
    86.2 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
    Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
    		[PMID: 19596885]
    CCRF-CEM CC50
    > 0.0001 M
    Compound: AZT
    Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1
    Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1
    		[PMID: 9871705]
    CCRF-CEM CC50
    > 1 μM
    Compound: AZT
    Tested for cytotoxic concentration in CEM-SS cell culture
    Tested for cytotoxic concentration in CEM-SS cell culture
    		[PMID: 11087582]
    CCRF-CEM CC50
    > 100 μM
    Compound: 1b; AZT
    Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
    Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
    		[PMID: 32515595]
    CCRF-CEM CC50
    > 100 μM
    Compound: 3 (AZT)
    Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.
    Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.
    		10.1016/0960-894X(96)00195-3
    CCRF-CEM CC50
    > 100 μM
    Compound: 3[AZT]
    Compound was evaluated for cytotoxic activity against CEM cells.
    Compound was evaluated for cytotoxic activity against CEM cells.
    		10.1016/0960-894X(96)00433-7
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    In vitro cytotoxic concentration in CEM cells.
    In vitro cytotoxic concentration in CEM cells.
    		[PMID: 10229629]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    Tested for cytotoxic concentration in CEM/TK- cell culture
    Tested for cytotoxic concentration in CEM/TK- cell culture
    		[PMID: 11087582]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
    		[PMID: 12593658]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity in CEM cells
    Cytotoxicity in CEM cells
    		[PMID: 16392791]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    Concentration required to reduce 50% of the number of CEM/O cells in the mock infected cell cultures.
    Concentration required to reduce 50% of the number of CEM/O cells in the mock infected cell cultures.
    		[PMID: 8765527]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    The cytotoxicity was measured on wild type CEM/O cells.
    The cytotoxicity was measured on wild type CEM/O cells.
    		[PMID: 9554875]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT
    Compound was tested for cytotoxicity against HIV-1 in CEM/TK- cells
    Compound was tested for cytotoxicity against HIV-1 in CEM/TK- cells
    		[PMID: 9873664]
    CCRF-CEM CC50
    > 100 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human thymidine kinase-deficient CEM cells
    Cytotoxicity against human thymidine kinase-deficient CEM cells
    		[PMID: 18585917]
    CCRF-CEM CC50
    > 100 μg/mL
    Compound: AZT
    Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
    Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
    		[PMID: 9046339]
    CCRF-CEM CC50
    > 125 μg/mL
    Compound: zidovudine
    Cytotoxic concentration required to reduce CEM cell viability by 50%
    Cytotoxic concentration required to reduce CEM cell viability by 50%
    		[PMID: 8709116]
    CCRF-CEM CC50
    > 250 μM
    Compound: 4, AZT
    Cytotoxicity against human CEM cells
    Cytotoxicity against human CEM cells
    		[PMID: 24177359]
    CCRF-CEM CC50
    > 250 μM
    Compound: AZT
    Concentration required to reduce cell viability of CEM/0 cells by 50%
    Concentration required to reduce cell viability of CEM/0 cells by 50%
    		10.1016/0960-894X(96)00443-X
    CCRF-CEM CC50
    > 250 μM
    Compound: AZT
    Concentration of compound required to reduce viability of CEM/0 cells by 50%.
    Concentration of compound required to reduce viability of CEM/0 cells by 50%.
    		10.1016/0960-894X(96)00444-1
    CCRF-CEM CC50
    > 250 μM
    Compound: AZT
    Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
    Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
    		[PMID: 26125628]
    CCRF-CEM CC50
    > 467.7 μM
    Compound: AZT
    Cytotoxicity against human CEM/0 cells
    Cytotoxicity against human CEM/0 cells
    		[PMID: 24411122]
    CCRF-CEM CC50
    > 500 μM
    Compound: 1
    cytotoxic activity in CEM/0 cell line
    cytotoxic activity in CEM/0 cell line
    		[PMID: 8478904]
    CCRF-CEM CC50
    > 500 μM
    Compound: 1
    Cytotoxic concentration against CEM cells (in vitro)
    Cytotoxic concentration against CEM cells (in vitro)
    		[PMID: 8648614]
    CCRF-CEM CC50
    > 500 μM
    Compound: AZT
    Concentration required to reduce CEM/0 cell viability by 50%
    Concentration required to reduce CEM/0 cell viability by 50%
    		[PMID: 11356105]
    CCRF-CEM EC50
    0.00032 μM
    Compound: N3ddThd
    Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells.
    Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells.
    		[PMID: 2153206]
    CCRF-CEM EC50
    0.0007 μg/mL
    Compound: AZT
    50% effective concentration of compound which is required to protect human CEM cells against HIV-1 induced giant cell formation.
    50% effective concentration of compound which is required to protect human CEM cells against HIV-1 induced giant cell formation.
    		[PMID: 9046339]
    CCRF-CEM EC50
    0.0009 μg/mL
    Compound: AZT
    50% effective concentration of compound which is required to protect human CEM cells against HIV-2 induced giant cell formation.
    50% effective concentration of compound which is required to protect human CEM cells against HIV-2 induced giant cell formation.
    		[PMID: 9046339]
    CCRF-CEM EC50
    0.003 μM
    Compound: 1
    Anti HIV-1 activity in human lymphocyte CEM/0 cell line
    Anti HIV-1 activity in human lymphocyte CEM/0 cell line
    		[PMID: 8478904]
    CCRF-CEM EC50
    0.003 μM
    Compound: 1
    Activity against HIV-1 in CEM cells (in vitro)
    Activity against HIV-1 in CEM cells (in vitro)
    		[PMID: 8648614]
    CCRF-CEM EC50
    0.003 μM
    Compound: AZT
    Anti-HIV activity against HIV-1 infected CEM/0 cell lines.
    Anti-HIV activity against HIV-1 infected CEM/0 cell lines.
    		10.1016/0960-894X(96)00443-X
    CCRF-CEM EC50
    0.003 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity against HIV-1 infected CEM/0 cell lines.
    Compound was evaluated for anti-HIV activity against HIV-1 infected CEM/0 cell lines.
    		10.1016/0960-894X(96)00444-1
    CCRF-CEM EC50
    0.003 μM
    Compound: AZT
    Tested for anti-HIV -1 Activity in CEM-SS cell culture
    Tested for anti-HIV -1 Activity in CEM-SS cell culture
    		[PMID: 11087582]
    CCRF-CEM EC50
    0.003 μM
    Compound: AZT
    Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells
    Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells
    		[PMID: 7527463]
    CCRF-CEM EC50
    0.003 μM
    Compound: n AZT
    Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
    Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
    		[PMID: 11714616]
    CCRF-CEM EC50
    0.004 μM
    Compound: 1
    Anti HIV-2 activity in human lymphocyte CEM/0 cell line
    Anti HIV-2 activity in human lymphocyte CEM/0 cell line
    		[PMID: 8478904]
    CCRF-CEM EC50
    0.004 μM
    Compound: 1
    Activity against HIV-2 in CEM cells (in vitro)
    Activity against HIV-2 in CEM cells (in vitro)
    		[PMID: 8648614]
    CCRF-CEM EC50
    0.004 μM
    Compound: AZT
    Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line
    Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line
    		[PMID: 12801219]
    CCRF-CEM EC50
    0.004 μM
    Compound: AZT
    Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line
    Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line
    		[PMID: 12801219]
    CCRF-CEM EC50
    0.004 μM
    Compound: AZT
    Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells
    Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells
    		[PMID: 7527463]
    CCRF-CEM EC50
    0.004 μM
    Compound: AZT
    Concentration required to reduce 50% of the number of CEM/O cells in the HIV-2 infected cell cultures.
    Concentration required to reduce 50% of the number of CEM/O cells in the HIV-2 infected cell cultures.
    		[PMID: 8765527]
    CCRF-CEM EC50
    0.004 μM
    Compound: n AZT
    Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
    Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
    		[PMID: 11714616]
    CCRF-CEM EC50
    0.005 μM
    Compound: 3 (AZT)
    Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
    Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
    		10.1016/0960-894X(96)00195-3
    CCRF-CEM EC50
    0.005 μM
    Compound: 3[AZT]
    Compound was evaluated for antiviral activity against HIV-1 (IIIB) infected CEM cells.
    Compound was evaluated for antiviral activity against HIV-1 (IIIB) infected CEM cells.
    		10.1016/0960-894X(96)00433-7
    CCRF-CEM EC50
    0.0055 μM
    Compound: AZT
    Antiviral activity against HIV1 IIIB in CEM cells
    Antiviral activity against HIV1 IIIB in CEM cells
    		[PMID: 16392791]
    CCRF-CEM EC50
    0.0055 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD in CEM cells
    Antiviral activity against HIV2 ROD in CEM cells
    		[PMID: 16392791]
    CCRF-CEM EC50
    0.006 μM
    Compound: AZT
    Anti-HIV activity against HIV-2 infected CEM/0 cell lines.
    Anti-HIV activity against HIV-2 infected CEM/0 cell lines.
    		10.1016/0960-894X(96)00443-X
    CCRF-CEM EC50
    0.006 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/0 cell lines.
    Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/0 cell lines.
    		10.1016/0960-894X(96)00444-1
    CCRF-CEM EC50
    0.006 μM
    Compound: AZT
    Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
    Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
    		[PMID: 11356105]
    CCRF-CEM EC50
    0.006 μM
    Compound: AZT
    Concentration required to reduce 50% of the number of CEM/O cells in the HIV-1 infected cell cultures.
    Concentration required to reduce 50% of the number of CEM/O cells in the HIV-1 infected cell cultures.
    		[PMID: 8765527]
    CCRF-CEM EC50
    0.006 μM
    Compound: AZT
    Antiviral activity was measured on HIV-2 in wild-type CEM/O cells
    Antiviral activity was measured on HIV-2 in wild-type CEM/O cells
    		[PMID: 9554875]
    CCRF-CEM EC50
    0.0064 μM
    Compound: AZT
    Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
    Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
    		[PMID: 11356105]
    CCRF-CEM EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 LAI infected in CEM cells
    Antiviral activity against HIV1 LAI infected in CEM cells
    		[PMID: 19153047]
    CCRF-CEM EC50
    0.007 μM
    Compound: AZT
    Antiviral activity was measured on HIV-1 in wild-type CEM/O cells
    Antiviral activity was measured on HIV-1 in wild-type CEM/O cells
    		[PMID: 9554875]
    CCRF-CEM EC50
    0.008 μM
    Compound: 3 (AZT)
    Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
    Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
    		10.1016/0960-894X(96)00195-3
    CCRF-CEM EC50
    0.008 μM
    Compound: 3[AZT]
    Compound was evaluated for antiviral activity against HIV-2 (ROD) infected CEM cells.
    Compound was evaluated for antiviral activity against HIV-2 (ROD) infected CEM cells.
    		10.1016/0960-894X(96)00433-7
    CCRF-CEM EC50
    0.011 μM
    Compound: 2 (AZT)
    Inhibitory effect against HIV-1 replication in CEM cells.
    Inhibitory effect against HIV-1 replication in CEM cells.
    		[PMID: 7538589]
    CCRF-CEM EC50
    0.011 μM
    Compound: 2 (AZT)
    Inhibitory effect against HIV-2 replication in CEM cells.
    Inhibitory effect against HIV-2 replication in CEM cells.
    		[PMID: 7538589]
    CCRF-CEM EC50
    0.012 μM
    Compound: 4, AZT
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 24177359]
    CCRF-CEM EC50
    0.023 μM
    Compound: AZT
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CCRF-CEM EC50
    0.067 μM
    Compound: 4, AZT
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 24177359]
    CCRF-CEM EC50
    0.186 μM
    Compound: AZT
    Effective concentration against HIV-1-infected CEM cells in mice administered intraperitoneally
    Effective concentration against HIV-1-infected CEM cells in mice administered intraperitoneally
    		[PMID: 8627600]
    CCRF-CEM EC50
    0.7 μM
    Compound: AZT
    Cytotoxicity against african human CEM cells after 6 days by XTT assay
    Cytotoxicity against african human CEM cells after 6 days by XTT assay
    		[PMID: 20691339]
    CCRF-CEM EC50
    1.05 μM
    Compound: AZT
    Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
    Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
    		[PMID: 21295891]
    CCRF-CEM EC50
    1.1 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
    Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
    		[PMID: 21227704]
    CCRF-CEM EC50
    3 nM
    Compound: 1
    In vitro inhibitory activity against replication of HIV-1 in human lymphocyte CEM cells
    In vitro inhibitory activity against replication of HIV-1 in human lymphocyte CEM cells
    		10.1016/0960-894X(94)80009-X
    CCRF-CEM EC50
    3.5 nM
    Compound: 1
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte CEM cells
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte CEM cells
    		10.1016/0960-894X(94)80009-X
    CCRF-CEM EC50
    < 0.001 μM
    Compound: AZT
    Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
    Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
    		[PMID: 11170632]
    CCRF-CEM EC50
    > 0.0001 M
    Compound: AZT
    Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1
    Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1
    		[PMID: 9871705]
    CCRF-CEM EC50
    > 100 μM
    Compound: 1
    Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase
    Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase
    		[PMID: 8478904]
    CCRF-CEM EC50
    > 100 μM
    Compound: 3 (AZT)
    Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
    Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
    		10.1016/0960-894X(96)00195-3
    CCRF-CEM EC50
    > 100 μM
    Compound: AZT
    Tested for anti-HIV -1 Activity in CEM/TK- cell culture
    Tested for anti-HIV -1 Activity in CEM/TK- cell culture
    		[PMID: 11087582]
    CCRF-CEM EC50
    > 100 μM
    Compound: AZT
    Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
    Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
    		[PMID: 12593658]
    CCRF-CEM EC50
    > 100 μM
    Compound: AZT
    Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells
    Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells
    		[PMID: 9554875]
    CCRF-CEM EC50
    > 100 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 infected human thymidine kinase-deficient CEM cells
    Antiviral activity against HIV1 infected human thymidine kinase-deficient CEM cells
    		[PMID: 18585917]
    CCRF-CEM EC50
    > 100000 nM
    Compound: 1
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte thymidine kinase deficient CEM cells
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte thymidine kinase deficient CEM cells
    		10.1016/0960-894X(94)80009-X
    CCRF-CEM EC50
    > 35 μM
    Compound: 2 (AZT)
    Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.
    Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.
    		[PMID: 7538589]
    CCRF-CEM EC50
    3.0 x 10-9 M
    Compound: AZT
    Tested for in vitro drug concentration which produces 50% survival of HIV-1 infected CEM cells relative to uninfected untreated controls
    Tested for in vitro drug concentration which produces 50% survival of HIV-1 infected CEM cells relative to uninfected untreated controls
    		[PMID: 7932583]
    CCRF-CEM EC50
    3.0 x 10-9 M
    Compound: AZT
    Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls
    Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls
    		[PMID: 7996541]
    CCRF-CEM ED50
    0.12 μM
    Compound: AZT
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
    		[PMID: 1712047]
    CCRF-CEM ED50
    0.12 μM
    Compound: AZT
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
    		[PMID: 1712047]
    CCRF-CEM ED50
    0.18 μM
    Compound: AZT
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
    		[PMID: 1712047]
    CCRF-CEM ED50
    0.45 μM
    Compound: AZT
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
    Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
    		[PMID: 1712047]
    CCRF-CEM IC50
    0.0005 M
    Compound: AZT
    Tested for in vitro drug concentration which results in 50% survival of uninfected untreated control CEM cells
    Tested for in vitro drug concentration which results in 50% survival of uninfected untreated control CEM cells
    		[PMID: 7932583]
    CCRF-CEM IC50
    0.0005 M
    Compound: AZT
    Inhibitory concentration (cytotoxic activity) which results in a 50% survival of HIV-1-infected CEM cells relative to uninfected untreated control cells
    Inhibitory concentration (cytotoxic activity) which results in a 50% survival of HIV-1-infected CEM cells relative to uninfected untreated control cells
    		[PMID: 7996541]
    CCRF-CEM IC50
    0.003 μg/mL
    Compound: AZT
    compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
    compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
    		[PMID: 9548818]
    CCRF-CEM IC50
    0.005 μg/mL
    Compound: Azidothymidine
    Inhibition of human immunodeficiency virus-1 (HIV-1) induced cytopathicity in CEM cells
    Inhibition of human immunodeficiency virus-1 (HIV-1) induced cytopathicity in CEM cells
    		[PMID: 8831773]
    CCRF-CEM IC50
    0.006 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.007 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.008 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells
    Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.008 μg/mL
    Compound: Azidothymidine
    Inhibition of human immunodeficiency virus-2 (HIV-2) induced cytopathicity in CEM cells
    Inhibition of human immunodeficiency virus-2 (HIV-2) induced cytopathicity in CEM cells
    		[PMID: 8831773]
    CCRF-CEM IC50
    0.01 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 infected CEM cell lines
    Inhibitory concentration against HIV-1 infected CEM cell lines
    		[PMID: 7837220]
    CCRF-CEM IC50
    0.014 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.017 μM
    Compound: AZT
    Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells
    Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.02 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.04 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.046 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.08 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.082 μM
    Compound: AZT
    Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells
    Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.087 μM
    Compound: AZT
    Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells
    Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    0.1 μM
    Compound: 1
    Concentration of compound required to inhibit 50% of viral replication of human immunodeficiency virus in CEM-F cells
    Concentration of compound required to inhibit 50% of viral replication of human immunodeficiency virus in CEM-F cells
    		[PMID: 2754712]
    CCRF-CEM IC50
    0.87 μM
    Compound: AZT
    Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells
    Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells
    		[PMID: 11708913]
    CCRF-CEM IC50
    1.04 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
    Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
    		[PMID: 20350812]
    CCRF-CEM IC50
    1.05 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
    Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
    		[PMID: 20137956]
    CCRF-CEM IC50
    13 μM
    Compound: AZT
    Cytotoxic concentration against CEM cells was determined on day 6
    Cytotoxic concentration against CEM cells was determined on day 6
    		[PMID: 8057301]
    CCRF-CEM IC50
    13 μM
    Compound: AZT
    Compound was evaluated for its toxicity by Calorimetric assay in CEM
    Compound was evaluated for its toxicity by Calorimetric assay in CEM
    		[PMID: 9357530]
    CCRF-CEM IC50
    14 μM
    Compound: AZT
    Cytotoxicity in CEM cells
    Cytotoxicity in CEM cells
    		10.1016/0960-894X(95)00133-E
    CCRF-CEM IC50
    14 μM
    Compound: AZT
    Compound was evaluated for cytotoxicity against CEM cells
    Compound was evaluated for cytotoxicity against CEM cells
    		10.1016/0960-894X(96)00171-0
    CCRF-CEM IC50
    14 μM
    Compound: AZT
    Compound was evaluated for its cytotoxicity against CEM cells.
    Compound was evaluated for its cytotoxicity against CEM cells.
    		[PMID: 9873395]
    CCRF-CEM IC50
    14.2 μM
    Compound: AZT
    Concentration required to kill 50% of CEM cells
    Concentration required to kill 50% of CEM cells
    		[PMID: 11170632]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
    Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
    		10.1007/s00044-011-9912-x
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Inhibitory activity was evaluated on mitochondrial DNA content of CEM cells
    Inhibitory activity was evaluated on mitochondrial DNA content of CEM cells
    		[PMID: 10197975]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    In vitro cytotoxicity in CEM cells.
    In vitro cytotoxicity in CEM cells.
    		[PMID: 11689085]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against CEM cells
    Cytotoxicity against CEM cells
    		[PMID: 11882000]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against CEM cells
    Cytotoxicity against CEM cells
    		[PMID: 12383014]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells
    Cytotoxicity against human CEM cells
    		[PMID: 16509580]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against CEM cells
    Cytotoxicity against CEM cells
    		[PMID: 17085053]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 6 days
    Cytotoxicity against human CEM cells after 6 days
    		[PMID: 17158051]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 3 days by MTT assay
    Cytotoxicity against human CEM cells after 3 days by MTT assay
    		[PMID: 19153047]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 5 days
    Cytotoxicity against human CEM cells after 5 days
    		[PMID: 19948402]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
    		[PMID: 21700368]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
    		[PMID: 22014549]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells
    Cytotoxicity against human CEM cells
    		[PMID: 24091080]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT
    Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    		[PMID: 25701249]
    CCRF-CEM IC50
    14.3 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human CEM cells
    Cytotoxicity against human CEM cells
    		[PMID: 23085031]
    CCRF-CEM IC50
    14.3 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration against CEM cell line
    Inhibitory concentration against CEM cell line
    		[PMID: 15916425]
    CCRF-CEM IC50
    14.3 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration against CEM cell line
    Inhibitory concentration against CEM cell line
    		[PMID: 15916425]
    CCRF-CEM IC50
    191 μM
    Compound: AZT
    Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
    Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
    		[PMID: 8627600]
    CCRF-CEM IC50
    29 μM
    Compound: AZT
    Evaluated in vitro for their potential toxic effects human CEM cells
    Evaluated in vitro for their potential toxic effects human CEM cells
    		[PMID: 12540238]
    CCRF-CEM IC50
    30.9 μM
    Compound: AZT
    Tested in vitro for anticancer activity against CEM cells
    Tested in vitro for anticancer activity against CEM cells
    		[PMID: 10072683]
    CCRF-CEM IC50
    30.9 μM
    Compound: AZT
    Cytotoxicity was determined in CEM cells, relative to RVT
    Cytotoxicity was determined in CEM cells, relative to RVT
    		[PMID: 15081000]
    CCRF-CEM IC50
    30.9 μM
    Compound: AZT
    Cytotoxicity against uninfected PHA-stimulated CEM cells was determined.
    Cytotoxicity against uninfected PHA-stimulated CEM cells was determined.
    		[PMID: 8421287]
    CCRF-CEM IC50
    301.6 μM
    Compound: AZT
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CCRF-CEM IC50
    35.6 μM
    Compound: AZT
    Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
    Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
    		[PMID: 20691339]
    CCRF-CEM IC50
    56.1 μM
    Compound: AZT
    Cytotoxicity against human CEM cells after 5 days by trypan blue assay
    Cytotoxicity against human CEM cells after 5 days by trypan blue assay
    		[PMID: 21371895]
    CCRF-CEM IC50
    7.7 μM
    Compound: AZT
    Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
    Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
    		[PMID: 22549138]
    CCRF-CEM IC50
    < 0.03 μg/mL
    Compound: AZT
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    		[PMID: 1738145]
    CCRF-CEM IC50
    > 100 μM
    Compound: 27, L-AZT
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
    		[PMID: 21700368]
    CCRF-CEM IC50
    > 100 μM
    Compound: AZT
    Compound was tested for inhibitory activity against HIV-1 replication in CEM/TK- cells
    Compound was tested for inhibitory activity against HIV-1 replication in CEM/TK- cells
    		[PMID: 9873664]
    CCRF-CEM IC50
    > 100 μM
    Compound: N3ddThd
    Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells.
    Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells.
    		[PMID: 2153206]
    CCRF-CEM IC50
    > 14.9 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    		[PMID: 24411122]
    CCRF-CEM IC50
    > 375 μM
    Compound: AZT
    Antiproliferative activity was determined against human T-lymphocyte cells-CEM
    Antiproliferative activity was determined against human T-lymphocyte cells-CEM
    		[PMID: 12801219]
    CEM-SS CC50
    > 0.1 μM
    Compound: AZT ; azidothymidine
    Cytotoxicity against mock-infected human CEM-SS cells
    Cytotoxicity against mock-infected human CEM-SS cells
    		[PMID: 27234889]
    CEM-SS CC50
    > 1 μM
    Compound: AZT
    Cytotoxicity against human CEM-SS cells by MTT assay
    Cytotoxicity against human CEM-SS cells by MTT assay
    		[PMID: 20112915]
    CEM-SS CC50
    > 1 μM
    Compound: AZT
    Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
    Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
    		[PMID: 21035347]
    CEM-SS CC50
    > 1 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    		[PMID: 9240351]
    CEM-SS CC50
    > 1 μM
    Compound: AZT, 3'-azidothymidine
    Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
    Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
    		[PMID: 24102161]
    CEM-SS CC50
    > 10 μM
    Compound: AZT
    Compound was evaluated for cytotoxicity against CEM SS cells infected with HIV-1(LAI strain).
    Compound was evaluated for cytotoxicity against CEM SS cells infected with HIV-1(LAI strain).
    		10.1016/0960-894X(95)00584-G
    CEM-SS CC50
    > 100 μM
    Compound: 1, AZT
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    		[PMID: 10821705]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration to inhibit HIV replication in TK CEM-SS cell line
    Cytotoxic concentration to inhibit HIV replication in TK CEM-SS cell line
    		[PMID: 11425558]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
    		[PMID: 12593658]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line
    Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line
    		[PMID: 14521418]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human CEM-SS cells by MTT assay
    Cytotoxicity against human CEM-SS cells by MTT assay
    		[PMID: 19944610]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    		[PMID: 7562927]
    CEM-SS CC50
    > 100 μM
    Compound: AZT
    Compound was tested for cytotoxicity against HIV-1 in CEM-SS cells
    Compound was tested for cytotoxicity against HIV-1 in CEM-SS cells
    		[PMID: 9873664]
    CEM-SS CC50
    > 100 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human CEM-SS cells
    Cytotoxicity against human CEM-SS cells
    		[PMID: 18585917]
    CEM-SS CC50
    > 1000 μM
    Compound: AZT
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    CEM-SS CC50
    > 100000 nM
    Compound: AZT
    Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line
    Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line
    		[PMID: 11052800]
    CEM-SS CC50
    > 100000 nM
    Compound: AZT
    Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.
    Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.
    		[PMID: 7473595]
    CEM-SS EC50
    0.0019 μM
    Compound: AZT
    Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control CEM-SS cells (in vitro anti-HIV activity)
    Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control CEM-SS cells (in vitro anti-HIV activity)
    		[PMID: 11462972]
    CEM-SS EC50
    0.0019 μM
    Compound: AZT
    Effective concentration against 50% survival of HIV -1 infected cells relative to uninfected untreated control (in vitro anti HIV-1 activity)
    Effective concentration against 50% survival of HIV -1 infected cells relative to uninfected untreated control (in vitro anti HIV-1 activity)
    		[PMID: 8709096]
    CEM-SS EC50
    0.002 μM
    Compound: 1, AZT
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    		[PMID: 10821705]
    CEM-SS EC50
    0.002 μM
    Compound: AZT ; azidothymidine
    Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
    Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
    		[PMID: 27234889]
    CEM-SS EC50
    0.003 μM
    Compound: AZT
    Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
    Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
    		[PMID: 12593658]
    CEM-SS EC50
    0.003 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 infected human CEM-SS cells
    Antiviral activity against HIV1 infected human CEM-SS cells
    		[PMID: 18585917]
    CEM-SS EC50
    0.0038 μM
    Compound: AZT
    The compound was tested for anti HIV activity in CEM-SS cell lines
    The compound was tested for anti HIV activity in CEM-SS cell lines
    		[PMID: 10411486]
    CEM-SS EC50
    0.004 μM
    Compound: AZT
    Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
    Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
    		[PMID: 7932526]
    CEM-SS EC50
    0.0045 μM
    Compound: AZT
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    		[PMID: 9240351]
    CEM-SS EC50
    0.0053 μM
    Compound: AZT, 3'-azidothymidine
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
    		[PMID: 24102161]
    CEM-SS EC50
    0.006 μM
    Compound: AZT
    Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line
    Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line
    		[PMID: 14521418]
    CEM-SS EC50
    0.006 μM
    Compound: AZT
    Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    		[PMID: 7562927]
    CEM-SS EC50
    0.0063 μM
    Compound: AZT
    Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells
    Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells
    		[PMID: 14698189]
    CEM-SS EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 infected in human CEM-SS cells assessed as virus induced cytopathic effects
    Antiviral activity against Human immunodeficiency virus 1 infected in human CEM-SS cells assessed as virus induced cytopathic effects
    		[PMID: 21035347]
    CEM-SS EC50
    0.009 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
    Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
    		[PMID: 20086159]
    CEM-SS EC50
    0.02 μM
    Compound: AZT
    Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
    Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
    		10.1016/0960-894X(95)00260-Z
    CEM-SS EC50
    0.095 μM
    Compound: AZT
    Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
    Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
    		[PMID: 7932526]
    CEM-SS EC50
    0.3 μM
    Compound: AZT
    Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
    Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
    		10.1016/0960-894X(95)00260-Z
    CEM-SS EC50
    11 nM
    Compound: AZT
    Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 2)
    Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 2)
    		[PMID: 10206539]
    CEM-SS EC50
    126 nM
    Compound: AZT
    Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1)
    Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1)
    		[PMID: 10206539]
    CEM-SS EC50
    2 nM
    Compound: 2, AZT
    Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
    Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
    		[PMID: 22858097]
    CEM-SS EC50
    > 100 μM
    Compound: AZT
    Effective concentration to inhibit HIV replication in TK CEM-SS cell line
    Effective concentration to inhibit HIV replication in TK CEM-SS cell line
    		[PMID: 11425558]
    CEM-SS IC50
    0.002 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    CEM-SS IC50
    0.002 μM
    Compound: AZT
    Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line
    Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line
    		[PMID: 7650678]
    CEM-SS IC50
    0.002 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-1 IIIB strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-1 IIIB strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.0024 μM
    Compound: AZT
    Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
    Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
    		[PMID: 20112915]
    CEM-SS IC50
    0.0026 μM
    Compound: Zidovudine (AZT)
    Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
    Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
    		[PMID: 9548815]
    CEM-SS IC50
    0.003 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.003 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    CEM-SS IC50
    0.003 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-1 RFstrain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-1 RFstrain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.0031 μM
    Compound: Zidovudine (AZT)
    Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
    Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
    		[PMID: 9548815]
    CEM-SS IC50
    0.004 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.004 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-1 LAV strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-1 LAV strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.005 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-2 A17 (pyridinone-res) strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-2 A17 (pyridinone-res) strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.005 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-2 ROD strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-2 ROD strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.0051 μM
    Compound: AZT
    Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
    Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
    		[PMID: 19944610]
    CEM-SS IC50
    0.006 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    CEM-SS IC50
    0.006 μM
    Compound: AZT
    Compound was tested for inhibitory activity against HIV-1 replication in CEM-SS cells
    Compound was tested for inhibitory activity against HIV-1 replication in CEM-SS cells
    		[PMID: 9873664]
    CEM-SS IC50
    0.007 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.01 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.015 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.028 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.03 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-2 MS strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-2 MS strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    0.04 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    0.08 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    CEM-SS IC50
    1.9 μM
    Compound: Zidovudine (AZT)
    Compounds were tested for cytotoxicity against CEM-SS cells in terms of incorporation of [3H]dThd
    Compounds were tested for cytotoxicity against CEM-SS cells in terms of incorporation of [3H]dThd
    		[PMID: 9548815]
    CEM-SS IC50
    3 nM
    Compound: AZT
    Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line
    Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line
    		[PMID: 11052800]
    CEM-SS IC50
    3 nM
    Compound: AZT
    Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells
    Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells
    		[PMID: 7473595]
    CEM-SS IC50
    3 μM
    Compound: AZT
    Compound was evaluated for antiviral activity against CEM SS cells infected with HIV-1(LAI strain).
    Compound was evaluated for antiviral activity against CEM SS cells infected with HIV-1(LAI strain).
    		10.1016/0960-894X(95)00584-G
    CEM-SS IC50
    5.1 mM
    Compound: AZT
    Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells
    Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells
    		[PMID: 1901911]
    CEM-SS IC50
    5.6 μM
    Compound: AZT
    In vitro inhibition of CEM-SS cell growth by 50 %
    In vitro inhibition of CEM-SS cell growth by 50 %
    		[PMID: 2016713]
    CEM-SS IC50
    > 0.1 μM
    Compound: AZT
    Cytotoxicity against human CEM-SS cells by MTS assay
    Cytotoxicity against human CEM-SS cells by MTS assay
    		[PMID: 20086149]
    CEM-SS IC50
    > 1 μM
    Compound: AZT
    The compound was tested for anti HIV activity in CEM-SS cell lines
    The compound was tested for anti HIV activity in CEM-SS cell lines
    		[PMID: 10411486]
    CEM-SS IC50
    > 1 μM
    Compound: AZT
    Concentration which results in 50% survival of uninfected untreated control CEM-SS cells (cytotoxicity of the compound)
    Concentration which results in 50% survival of uninfected untreated control CEM-SS cells (cytotoxicity of the compound)
    		[PMID: 11462972]
    CEM-SS IC50
    > 1 μM
    Compound: AZT
    Inhibitory activity against the cytopathic effect of HIV-2 G910-6(AZT-res) strain in CEM-SS cells
    Inhibitory activity against the cytopathic effect of HIV-2 G910-6(AZT-res) strain in CEM-SS cells
    		[PMID: 7650678]
    CEM-SS IC50
    > 1 μM
    Compound: AZT
    Cytotoxic concentration against 50% survival of uninfected untreated control CEM-SS cells
    Cytotoxic concentration against 50% survival of uninfected untreated control CEM-SS cells
    		[PMID: 8709096]
    CEM-SS IC50
    > 1887 μM
    Compound: AZT
    Compound was evaluated for inhibitory activity against cell growth
    Compound was evaluated for inhibitory activity against cell growth
    		10.1016/0960-894X(95)00260-Z
    CEM-SS IC50
    > 1887 μM
    Compound: AZT
    Compound was evaluated for inhibitory activity against cell growth
    Compound was evaluated for inhibitory activity against cell growth
    		10.1016/0960-894X(95)00260-Z
    CEM-TK(+) CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line
    Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line
    		[PMID: 14521418]
    CEM-TK(+) CC50
    > 100 μM
    Compound: AZT
    Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    		[PMID: 7562927]
    CEM-TK(+) EC50
    > 100 μM
    Compound: 1
    Activity against HIV-1 in CEM/TK cells (in vitro)
    Activity against HIV-1 in CEM/TK cells (in vitro)
    		[PMID: 8648614]
    CEM-TK(+) EC50
    > 100 μM
    Compound: AZT
    Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    		[PMID: 7562927]
    CEM-TK(+) EC50
    > 100 μM
    Compound: AZT
    Concentration required to reduce 50% of the number of CEM/TK cells in the HIV-2 infected cell cultures.
    Concentration required to reduce 50% of the number of CEM/TK cells in the HIV-2 infected cell cultures.
    		[PMID: 8765527]
    CEM-TK(+) EC50
    > 250 μM
    Compound: AZT
    Anti-HIV activity against HIV-2 infected CEM/TK- cell lines.
    Anti-HIV activity against HIV-2 infected CEM/TK- cell lines.
    		10.1016/0960-894X(96)00443-X
    CEM-TK(+) EC50
    > 250 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/TK- cell lines.
    Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/TK- cell lines.
    		10.1016/0960-894X(96)00444-1
    CEM-TK(-) CC50
    > 1000 μM
    Compound: AZT
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    CEM-TK(-) CC50
    > 200 μg/mL
    Compound: AZT
    Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
    Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
    		[PMID: 9046339]
    CEM-TK(-) EC50
    > 100 μM
    Compound: AZT
    Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
    Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
    		[PMID: 11356105]
    CEM-TK(-) EC50
    > 25 μg/mL
    Compound: AZT
    50% effective concentration of compound which is required to protect Thymidine kinase deficient human CEM (CEM/TK-) cells against HIV-2.
    50% effective concentration of compound which is required to protect Thymidine kinase deficient human CEM (CEM/TK-) cells against HIV-2.
    		[PMID: 9046339]
    CEM-c113 CC50
    > 5 μM
    Compound: AZT
    Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
    Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
    		[PMID: 9154976]
    CEM-c113 EC50
    0.006 μM
    Compound: AZT
    Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
    Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
    		[PMID: 8385224]
    CEM-c113 IC50
    20 μM
    Compound: AZT
    Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants
    Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants
    		[PMID: 8385224]
    CFU-GM IC50
    1.5 μM
    Compound: AZT
    Compound was tested for inhibitory activity against human myeloid cells (CFU-GM)
    Compound was tested for inhibitory activity against human myeloid cells (CFU-GM)
    		[PMID: 8057301]
    Caco-2 CC50
    56.1 μM
    Compound: AZT
    Cytotoxicity against human Caco-2 cells after 72 hrs
    Cytotoxicity against human Caco-2 cells after 72 hrs
    		[PMID: 17548129]
    Caco-2 CC50
    56.1 μM
    Compound: AZT
    Cytotoxicity against human Caco-2 cells after 72 hrs
    Cytotoxicity against human Caco-2 cells after 72 hrs
    		[PMID: 18037195]
    Caco-2 IC50
    0.006 mg/mL
    Compound: AZT
    Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
    Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
    		[PMID: 17337193]
    Caco-2 IC50
    0.015 mg/mL
    Compound: AZT
    Cytotoxicity against human Caco-2 cells after 72 hrs
    Cytotoxicity against human Caco-2 cells after 72 hrs
    		[PMID: 17079149]
    Caco-2 IC50
    0.015 mg/mL
    Compound: AZT
    Growth inhibition of human Caco-2 cells after 72 hrs
    Growth inhibition of human Caco-2 cells after 72 hrs
    		[PMID: 17079149]
    Caco-2 IC50
    0.02 mg/mL
    Compound: AZT
    Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection
    Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection
    		[PMID: 17337193]
    Caco-2 IC50
    22.39 μM
    Compound: AZT
    Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
    Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
    		[PMID: 17555969]
    Caco-2 IC50
    22.45 μM
    Compound: AZT
    Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
    Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
    		[PMID: 17337193]
    Caco-2 IC50
    22.45 μM
    Compound: AZT
    Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as inhibition of infectivity following virus attachment
    Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as inhibition of infectivity following virus attachment
    		[PMID: 17548129]
    Caco-2 IC50
    22.45 μM
    Compound: AZT
    Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
    Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
    		[PMID: 18037195]
    Caco-2 IC50
    74.62 μM
    Compound: AZT
    Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
    Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
    		[PMID: 17555969]
    Caco-2 IC50
    74.84 μM
    Compound: AZT
    Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection
    Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection
    		[PMID: 17337193]
    Caco-2 IC50
    74.84 μM
    Compound: AZT
    Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as neutralization of virus in the solution before attachment
    Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as neutralization of virus in the solution before attachment
    		[PMID: 17548129]
    Caco-2 IC50
    74.84 μM
    Compound: AZT
    Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
    Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
    		[PMID: 18037195]
    DU-145 IC50
    34.45 μM
    Compound: 13, AZT
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    FM3A IC50
    203 μM
    Compound: AZT
    Inhibitory effect of compound on the proliferation of murine mammary carcinoma cells FM3A/0
    Inhibitory effect of compound on the proliferation of murine mammary carcinoma cells FM3A/0
    		[PMID: 11356105]
    Fibroblast IC50
    0.02 μg/mL
    Compound: Azidothymidine
    Compound was tested for anti-retroviral activity against moloney murine sarcoma virus (MSV) in murine C3H/3T3 embryo fibroblast cell culture
    Compound was tested for anti-retroviral activity against moloney murine sarcoma virus (MSV) in murine C3H/3T3 embryo fibroblast cell culture
    		[PMID: 8831773]
    H9 CC50
    1873 μM
    Compound: AZT
    Cytotoxicity against human H9 cells after 6 days by XTT assay
    Cytotoxicity against human H9 cells after 6 days by XTT assay
    		[PMID: 20527972]
    H9 CC50
    200 μM
    Compound: AZT
    Cytotoxic concentration against HIV-1 infected H9 cell lines
    Cytotoxic concentration against HIV-1 infected H9 cell lines
    		[PMID: 7837220]
    H9 EC50
    0.001 μM
    Compound: AZT
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    H9 EC50
    0.001 μM
    Compound: AZT
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    H9 EC50
    0.00289 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
    		[PMID: 11678650]
    H9 EC50
    0.002 μg/mL
    Compound: AZT
    Cytotoxicity against mock-infected human H9 cells after 4 days
    Cytotoxicity against mock-infected human H9 cells after 4 days
    		[PMID: 8946749]
    H9 EC50
    0.009 μM
    Compound: AZT
    Evaluation for anti-HIV activity using T cell line (H9).
    Evaluation for anti-HIV activity using T cell line (H9).
    		10.1016/S0960-894X(97)10108-1
    H9 EC50
    0.01 μM
    Compound: AZT
    Cytotoxicity against human H9 cells after 6 days by MTT assay
    Cytotoxicity against human H9 cells after 6 days by MTT assay
    		[PMID: 20846868]
    H9 EC50
    0.012 μg/mL
    Compound: AZT
    Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
    Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
    		[PMID: 10021911]
    H9 EC50
    0.012 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
    		[PMID: 10757718]
    H9 EC50
    0.012 μg/mL
    Compound: AZT
    Cytotoxicity against mock-infected human H9 cells after 4 days
    Cytotoxicity against mock-infected human H9 cells after 4 days
    		[PMID: 9748372]
    H9 EC50
    0.0137 μM
    Compound: AZT
    Antiviral activity against HIV replication in H9 cells
    Antiviral activity against HIV replication in H9 cells
    		[PMID: 17533128]
    H9 EC50
    0.015 μM
    Compound: AZT
    Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
    Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
    		[PMID: 9804704]
    H9 EC50
    0.015 μM
    Compound: AZT
    Anti-HIV activity was measured in H9-cells.
    Anti-HIV activity was measured in H9-cells.
    		[PMID: 9804704]
    H9 EC50
    0.015 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity in H9 lymphocytes
    Compound was evaluated for anti-HIV activity in H9 lymphocytes
    		[PMID: 9871747]
    H9 EC50
    0.01 μg/mL
    Compound: AZT
    Antiviral activity against HIV-1(IIIB) infected H9 cell lines.
    Antiviral activity against HIV-1(IIIB) infected H9 cell lines.
    		[PMID: 11720855]
    H9 EC50
    0.01 μg/mL
    Compound: AZT
    Antiviral activity against HIV infected in human H9 cells assessed as viral replication
    Antiviral activity against HIV infected in human H9 cells assessed as viral replication
    		[PMID: 9584397]
    H9 EC50
    0.0221 μg/mL
    Compound: AZT
    Effective concentration against HIV-1 replication in H9 lymphocytic cells
    Effective concentration against HIV-1 replication in H9 lymphocytic cells
    		[PMID: 12729671]
    H9 EC50
    0.023 μM
    Compound: AZT
    Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
    Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
    		[PMID: 17190445]
    H9 EC50
    0.037 μM
    Compound: AZT
    Anti-HIV activity was measured in H9-cells by MAGI assay
    Anti-HIV activity was measured in H9-cells by MAGI assay
    		[PMID: 9804704]
    H9 EC50
    0.04 μM
    Compound: AZT
    Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
    Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
    		10.1016/S0960-894X(01)81071-4
    H9 EC50
    0.04 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    		[PMID: 8158164]
    H9 EC50
    0.04 μM
    Compound: AZT
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    		[PMID: 8176401]
    H9 EC50
    0.044 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
    Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
    		[PMID: 20187635]
    H9 EC50
    0.045 M
    Compound: AZT
    Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
    Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
    		[PMID: 15149703]
    H9 EC50
    0.045 μM
    Compound: AZT
    Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
    Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
    		10.1016/S0960-894X(97)10050-6
    H9 EC50
    0.045 μM
    Compound: AZT
    Concentration required to inhibit HIV-1 replication in H9 lymphocyte cells
    Concentration required to inhibit HIV-1 replication in H9 lymphocyte cells
    		[PMID: 10843202]
    H9 EC50
    0.045 μM
    Compound: AZT
    Cytotoxicity against mock-infected human H9 cells
    Cytotoxicity against mock-infected human H9 cells
    		[PMID: 11141100]
    H9 EC50
    0.045 μM
    Compound: AZT
    Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells
    Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells
    		[PMID: 11206454]
    H9 EC50
    0.045 μM
    Compound: AZT
    Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
    		[PMID: 11473435]
    H9 EC50
    0.045 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 replication in acutely infected H9 lymphocytes
    Inhibitory concentration against HIV-1 replication in acutely infected H9 lymphocytes
    		[PMID: 11527717]
    H9 EC50
    0.045 μM
    Compound: AZT
    Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes
    Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes
    		[PMID: 12699758]
    H9 EC50
    0.045 μM
    Compound: AZT
    Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
    Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
    		[PMID: 9873374]
    H9 EC50
    0.045 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity in acutely infected H9 Lymphocytes
    Compound was evaluated for anti-HIV activity in acutely infected H9 Lymphocytes
    		[PMID: 9873504]
    H9 EC50
    0.045 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
    Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
    		[PMID: 9917290]
    H9 EC50
    0.05 μM
    Compound: AZT
    Antiviral activity against HIV1 3B replication in H9 cells
    Antiviral activity against HIV1 3B replication in H9 cells
    		[PMID: 17719228]
    H9 EC50
    0.052 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
    		[PMID: 20527972]
    H9 EC50
    0.15 μM
    Compound: AZT
    Effective concentration against HIV-1 replication in H9 lymphocyte cells was determined
    Effective concentration against HIV-1 replication in H9 lymphocyte cells was determined
    		10.1016/S0960-894X(01)80161-X
    H9 EC50
    0.15 μM
    Compound: a AZT
    Toxic concentration on HIV-1 mock infected H9 lymphocyte cells
    Toxic concentration on HIV-1 mock infected H9 lymphocyte cells
    		[PMID: 8676334]
    H9 EC50
    4.5 μM
    Compound: AZT
    Inhibitory activity against HIV-1 replication in H9 lymphocytes
    Inhibitory activity against HIV-1 replication in H9 lymphocytes
    		[PMID: 11262077]
    H9 EC50
    50000 μg/mL
    Compound: AZT
    Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV
    Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV
    		[PMID: 9584397]
    H9 EC50
    > 20 μM
    Compound: AZT
    Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells
    Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells
    		[PMID: 9154967]
    H9 ED50
    0.04 μg/mL
    Compound: AZT
    Effective dose required to inhibit virus replication growth by 50%
    Effective dose required to inhibit virus replication growth by 50%
    		[PMID: 8642556]
    H9 IC50
    0.001 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    H9 IC50
    0.002 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    H9 IC50
    0.027 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    H9 IC50
    0.03 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
    In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
    		[PMID: 1573638]
    H9 IC50
    0.07 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 infected H9 cell lines
    Inhibitory concentration against HIV-1 infected H9 cell lines
    		[PMID: 7837220]
    H9 IC50
    150 μM
    Compound: 1
    Evaluated in vitro for the concentration required to produce 50% inhibition of proliferation of H9 lymphocytes
    Evaluated in vitro for the concentration required to produce 50% inhibition of proliferation of H9 lymphocytes
    		[PMID: 2329572]
    H9 IC50
    1870 μM
    Compound: AZT
    Cytotoxicity against human H9 cells after 4 days
    Cytotoxicity against human H9 cells after 4 days
    		[PMID: 17190445]
    H9 IC50
    1871 μM
    Compound: AZT
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    		[PMID: 11141100]
    H9 IC50
    1872 μM
    Compound: AZT
    Concentration required to inhibit uninfected H9 cell growth by 50%
    Concentration required to inhibit uninfected H9 cell growth by 50%
    		[PMID: 14736256]
    H9 IC50
    1873 μM
    Compound: AZT
    Evaluated for the anti-HIV activity against HIV-1 replication in mock-infected H9 cells
    Evaluated for the anti-HIV activity against HIV-1 replication in mock-infected H9 cells
    		[PMID: 11206454]
    H9 IC50
    1873 μM
    Compound: AZT
    Concentration required to produce 50% toxicity against mock-infected H9 cells
    Concentration required to produce 50% toxicity against mock-infected H9 cells
    		[PMID: 15501054]
    H9 IC50
    1875 μM
    Compound: AZT
    Compound was tested for inhibitory activity against HIV-1 replication in H9 lymphocyte cells
    Compound was tested for inhibitory activity against HIV-1 replication in H9 lymphocyte cells
    		10.1016/S0960-894X(01)80161-X
    H9 IC50
    1875 μM
    Compound: AZT
    Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
    Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
    		10.1016/S0960-894X(97)10050-6
    H9 IC50
    1875 μM
    Compound: AZT
    Concentration required to inhibit uninfected H9 cell growth
    Concentration required to inhibit uninfected H9 cell growth
    		[PMID: 10843202]
    H9 IC50
    1875 μM
    Compound: AZT
    Inhibition of HIV replication was determined in H9 lymphocytes
    Inhibition of HIV replication was determined in H9 lymphocytes
    		[PMID: 11262077]
    H9 IC50
    1875 μM
    Compound: AZT
    Cytotoxicity against human H9 cells
    Cytotoxicity against human H9 cells
    		[PMID: 11473435]
    H9 IC50
    1875 μM
    Compound: AZT
    Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
    Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
    		[PMID: 11527717]
    H9 IC50
    1875 μM
    Compound: AZT
    Concentration required to inhibit uninfected H9 cell growth by 50%
    Concentration required to inhibit uninfected H9 cell growth by 50%
    		[PMID: 15149703]
    H9 IC50
    1875 μM
    Compound: AZT
    Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
    Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
    		[PMID: 9873374]
    H9 IC50
    1875 μM
    Compound: AZT
    Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
    Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
    		[PMID: 9873504]
    H9 IC50
    1875 μM
    Compound: a AZT
    Inhibitory activity against HIV-1 replication in mock infected H9 cells
    Inhibitory activity against HIV-1 replication in mock infected H9 cells
    		[PMID: 8676334]
    H9 IC50
    1875 μg/mL
    Compound: AZT
    Cytotoxicity against human H9 cells
    Cytotoxicity against human H9 cells
    		[PMID: 9917290]
    H9 IC50
    1900 μM
    Compound: AZT
    Reduction in cell viability of human H9 cells
    Reduction in cell viability of human H9 cells
    		[PMID: 17719228]
    H9 IC50
    2000 μM
    Compound: AZT
    Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
    Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
    		10.1016/S0960-894X(01)81071-4
    H9 IC50
    2000 μM
    Compound: AZT
    Cytotoxicity against human H9 cells after 3 days
    Cytotoxicity against human H9 cells after 3 days
    		[PMID: 8158164]
    H9 IC50
    2000 μM
    Compound: AZT
    Cytotoxicity against human H9 cells after 3 days
    Cytotoxicity against human H9 cells after 3 days
    		[PMID: 8176401]
    H9 IC50
    2000 μg/mL
    Compound: AZT
    Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
    Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
    		[PMID: 8642556]
    H9 IC50
    50 nM
    Compound: AZT
    Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
    Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
    		10.1016/0960-894X(95)00306-E
    H9 IC50
    500 μM
    Compound: AZT
    Cytotoxicity against H9 cell line
    Cytotoxicity against H9 cell line
    		10.1016/S0960-894X(97)10108-1
    H9 IC50
    500 μM
    Compound: AZT
    Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes
    Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes
    		[PMID: 12699758]
    H9 IC50
    500 μM
    Compound: AZT
    Cytotoxicity against H9 cells assessed as growth inhibition
    Cytotoxicity against H9 cells assessed as growth inhibition
    		[PMID: 17533128]
    H9 IC50
    500 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
    		[PMID: 20846868]
    H9 IC50
    500 μM
    Compound: AZT
    Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.
    Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.
    		[PMID: 9804704]
    H9 IC50
    500 μM
    Compound: AZT
    Compound was evaluated for cytotoxicity in H9 lymphocytes
    Compound was evaluated for cytotoxicity in H9 lymphocytes
    		[PMID: 9871747]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
    Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
    		[PMID: 10021911]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Cytotoxicity against human H9 cells
    Cytotoxicity against human H9 cells
    		[PMID: 10757718]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Cytotoxicity against human H9 cells
    Cytotoxicity against human H9 cells
    		[PMID: 11678650]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.
    Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.
    		[PMID: 11720855]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Concentration that inhibits uninfected H9 cell growth by 50%.
    Concentration that inhibits uninfected H9 cell growth by 50%.
    		[PMID: 12729671]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
    		[PMID: 8946749]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Cytotoxicity against human H9 cells
    Cytotoxicity against human H9 cells
    		[PMID: 9584397]
    H9 IC50
    500 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    		[PMID: 9748372]
    H9 IC50
    500 μg/mL
    Compound: azt
    Cytotoxicity against mock-infected human H9 lymphocytes
    Cytotoxicity against mock-infected human H9 lymphocytes
    		[PMID: 16989518]
    H9 IC50
    < 0.0003 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    H9 IC50
    < 0.0003 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    H9 IC50
    < 0.0003 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
    		[PMID: 20086149]
    H9 IC50
    > 0.1 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    H9 IC50
    > 0.1 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
    		[PMID: 20086149]
    H9 IC50
    > 0.1 μM
    Compound: AZT
    Cytotoxicity against human H9 cells by MTS assay
    Cytotoxicity against human H9 cells by MTS assay
    		[PMID: 20086149]
    H9 IC50
    > 1872 μM
    Compound: AZT
    Concentration required to inhibit 50% growth of uninfected H9 cells
    Concentration required to inhibit 50% growth of uninfected H9 cells
    		[PMID: 15501055]
    HEK-293T CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
    Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
    		[PMID: 17470654]
    HEK-293T EC50
    200 nM
    Compound: AZT
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    		[PMID: 22148316]
    HEK-293T EC50
    6 nM
    Compound: AZT
    Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    		[PMID: 22148316]
    HFF IC50
    > 100 μM
    Compound: Zidovudine (AZT)
    Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 7562946]
    HL-60 IC50
    96 μM
    Compound: AZT
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    		[PMID: 1695683]
    HOS IC50
    1.4 μM
    Compound: AZT
    Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    		[PMID: 19678643]
    HOS IC50
    20.1 μM
    Compound: AZT
    Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    		[PMID: 19678643]
    HOS IC50
    3.6 μM
    Compound: AZT
    Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    		[PMID: 19678643]
    HOS IC50
    39.6 μM
    Compound: AZT
    Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
    		[PMID: 19678643]
    HeLa CC50
    > 25 μM
    Compound: Zidovudine
    Cytotoxicity against mock-infected human HeLa cells by MTT assay
    Cytotoxicity against mock-infected human HeLa cells by MTT assay
    		[PMID: 25682562]
    HeLa CC50
    > 270 μM
    Compound: AZT
    Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
    Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
    		[PMID: 19596885]
    HeLa EC50
    0.002 μM
    Compound: AZT
    Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
    Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
    		[PMID: 11087576]
    HeLa EC50
    0.009 μM
    Compound: AZT
    Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
    Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
    		[PMID: 9258355]
    HeLa EC50
    0.013 μM
    Compound: AZT
    Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
    Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
    		[PMID: 9258355]
    HeLa EC50
    10.8 μM
    Compound: 2, AZT, Zidovudine
    Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
    		[PMID: 22352809]
    HeLa EC50
    14.2 μM
    Compound: 2, AZT, Zidovudine
    Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
    		[PMID: 22352809]
    HeLa EC50
    2.9 μM
    Compound: AZT
    Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
    Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
    		[PMID: 9258355]
    HeLa EC50
    > 374 μM
    Compound: 2, AZT, Zidovudine
    Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
    		[PMID: 22352809]
    HeLa IC50
    0.04 μM
    Compound: AZT
    Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
    Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
    		[PMID: 22858300]
    HeLa IC50
    0.18 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    0.19 μM
    Compound: AZT
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    0.21 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    0.21 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    10.4 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    10.77 μM
    Compound: 3; AZT
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    HeLa IC50
    10.77 μM
    Compound: AZT
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    HeLa IC50
    11.9 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    204.6 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    213.7 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    58.6 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    65.46 μM
    Compound: 13, AZT
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    		[PMID: 25933593]
    HeLa IC50
    96.7 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    HeLa IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 22858300]
    HeLa IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    HeLa IC50
    > 100 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
    		[PMID: 17416522]
    HeLa IC50
    > 100 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
    		[PMID: 17416522]
    HepG2 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 25458500]
    HepG2 IC50
    13.03 μM
    Compound: 3; AZT
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    HepG2 IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    HepG2 IC50
    > 400 μM
    Compound: Azidothymidine
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 31546197]
    HepG2 IC50
    > 479 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 25442310]
    HepG2 IC50
    > 479 μM
    Compound: AZT; Zidovudine
    Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
    		[PMID: 27342752]
    HepG2 2.2.15 EC50
    > 10 μM
    Compound: AZT
    Antiviral activity against Hepatitis-B virus 2.2.15(HBV)
    Antiviral activity against Hepatitis-B virus 2.2.15(HBV)
    		[PMID: 9357530]
    Huh-7 CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
    Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
    		[PMID: 22014549]
    Huh-7 CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
    Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
    		[PMID: 23623492]
    Huh-7 EC50
    > 10 μM
    Compound: AZT
    Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
    Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
    		[PMID: 22014549]
    Huh-7 EC50
    > 10 μM
    Compound: AZT
    Antiviral activity against Hepatitis C virus infected in human HuH7 cells
    Antiviral activity against Hepatitis C virus infected in human HuH7 cells
    		[PMID: 23623492]
    JM1 CC50
    > 1000 μM
    Compound: AZT
    Concentration required to reduce cell viability of JM cells by 50%
    Concentration required to reduce cell viability of JM cells by 50%
    		10.1016/0960-894X(96)00443-X
    JM1 EC50
    200 μM
    Compound: AZT
    Anti-HIV activity against HIV-1 infected JM cell lines
    Anti-HIV activity against HIV-1 infected JM cell lines
    		10.1016/0960-894X(96)00443-X
    JM1 ED50
    100 μM
    Compound: 1
    Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control
    Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control
    		10.1016/S0960-894X(00)80395-9
    Jurkat CC50
    > 500 μM
    Compound: AZT
    Cytotoxic concentration against HIV-1 infected Jurkat cell lines
    Cytotoxic concentration against HIV-1 infected Jurkat cell lines
    		[PMID: 7837220]
    Jurkat EC50
    0.09 μM
    Compound: AZT
    Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
    Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
    		[PMID: 22954898]
    Jurkat IC50
    0.01 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 infected Jurkat cell lines
    Inhibitory concentration against HIV-1 infected Jurkat cell lines
    		[PMID: 7837220]
    Jurkat IC50
    120 nM
    Compound: AZT
    Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
    Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
    		[PMID: 21414776]
    KB IC50
    3.12 μg/mL
    Compound: AZT, Zidovudine
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    KB IC50
    9.77 μM
    Compound: 3; AZT
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    KB IC50
    9.77 μM
    Compound: AZT
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    KB IC50
    > 400 μM
    Compound: Azidothymidine
    Antiproliferative activity against human KB cells by MTT assay
    Antiproliferative activity against human KB cells by MTT assay
    		[PMID: 31546197]
    KB IC50
    > 479 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 25442310]
    KB 3-1 IC50
    9.17 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    L1210 IC50
    6.18 μM
    Compound: AZT
    Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/0.
    Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/0.
    		[PMID: 11356105]
    L1210/TK- IC50
    > 500 μM
    Compound: AZT
    Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/TK-
    Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/TK-
    		[PMID: 11356105]
    M EC50
    0.015 μM
    Compound: AZT
    Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
    Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
    		[PMID: 7932526]
    MCF7 IC50
    13.74 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    MCF7 IC50
    2.6 μg/mL
    Compound: AZT, Zidovudine
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    		[PMID: 21945463]
    MCF7 IC50
    34.97 μM
    Compound: 13, AZT
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    MCF7 IC50
    7.67 μM
    Compound: AZT
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    MCF7 IC50
    > 10 μM
    Compound: AZT
    Tested in vitro for anticancer activity against MCF-7 cells
    Tested in vitro for anticancer activity against MCF-7 cells
    		[PMID: 10072683]
    MCF7 IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    MOLT-3 CC50
    12.1 μM
    Compound: AZT
    Cytotoxicity against human MOLT3 cells by MTS assay
    Cytotoxicity against human MOLT3 cells by MTS assay
    		[PMID: 22549138]
    MOLT-3 CC50
    3.24 μg/mL
    Compound: AZT
    Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
    Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
    		[PMID: 21334901]
    MOLT-4 EC50
    6.2 nM
    Compound: AZT
    Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells
    Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells
    		[PMID: 10866387]
    MOLT-4 EC50
    > 10 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
    Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
    		[PMID: 18316521]
    MOLT-4 IC50
    62.8 μM
    Compound: AZT
    Inhibitory effect of compound on the proliferation of human T-lymphocyte cells Molt4/C8
    Inhibitory effect of compound on the proliferation of human T-lymphocyte cells Molt4/C8
    		[PMID: 11356105]
    MOLT-4 IC50
    > 375 μM
    Compound: AZT
    Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8
    Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8
    		[PMID: 12801219]
    MT2 CC50
    123 μM
    Compound: AZT
    Tested for the drug concentration required to decrease HIV-1IIIb infected MT-2 cell viability compared to uninfected controls
    Tested for the drug concentration required to decrease HIV-1IIIb infected MT-2 cell viability compared to uninfected controls
    		[PMID: 7512142]
    MT2 CC50
    150 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
    Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
    		[PMID: 19596885]
    MT2 CC50
    1870 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells by XTT assay
    Cytotoxicity against human MT2 cells by XTT assay
    		[PMID: 19388685]
    MT2 CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against MT2 cells
    Cytotoxicity against MT2 cells
    		[PMID: 15615545]
    MT2 CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against MT2 cells
    Cytotoxicity against MT2 cells
    		[PMID: 17004726]
    MT2 CC50
    > 10 μM
    Compound: AZT
    Cytotoxic concentration against MT-2 cells
    Cytotoxic concentration against MT-2 cells
    		[PMID: 7684450]
    MT2 CC50
    > 100 μM
    Compound: AZT
    Anti-HIV activity based on reduction of the viability of mock-infected MT-2 cells.
    Anti-HIV activity based on reduction of the viability of mock-infected MT-2 cells.
    		[PMID: 12699395]
    MT2 CC50
    > 200 μM
    Compound: 3
    Cytotoxicity against MT2 cells
    Cytotoxicity against MT2 cells
    		[PMID: 17562366]
    MT2 CC50
    > 200 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells
    Cytotoxicity against human MT2 cells
    		[PMID: 18164198]
    MT2 CC50
    > 200 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    		[PMID: 20542430]
    MT2 CC50
    > 200 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human MT2 cells after 5 days
    Cytotoxicity against human MT2 cells after 5 days
    		[PMID: 19179082]
    MT2 CC50
    >= 25 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    		[PMID: 23570720]
    MT2 EC50
    0.0012 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0029 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.003 μM
    Compound: AZT
    Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
    Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
    		[PMID: 7932526]
    MT2 EC50
    0.0038 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0049 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.005 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells
    Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells
    		[PMID: 18316521]
    MT2 EC50
    0.0063 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells
    Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells
    		[PMID: 18316521]
    MT2 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.014 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.014 μM
    Compound: AZT
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 EC50
    0.016 μM
    Compound: AZT
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    		[PMID: 18316521]
    MT2 EC50
    0.018 μM
    Compound: AZT
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.02 μM
    Compound: AZT
    Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
    Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
    		[PMID: 17004726]
    MT2 EC50
    0.027 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.029 μM
    Compound: AZT
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT2 EC50
    0.03 μM
    Compound: AZT
    Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI
    Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI
    		[PMID: 12852759]
    MT2 EC50
    0.034 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
    		[PMID: 20329730]
    MT2 EC50
    0.037 μM
    Compound: AZT
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 EC50
    0.038 μM
    Compound: AZT
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.043 μM
    Compound: AZT
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.044 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
    		[PMID: 20537902]
    MT2 EC50
    0.051 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.054 μM
    Compound: AZT
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.056 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
    		[PMID: 19388685]
    MT2 EC50
    0.075 μM
    Compound: AZT
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.087 μM
    Compound: AZT
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.117 μM
    Compound: AZT
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.144 μM
    Compound: AZT
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.16 μM
    Compound: 3
    Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
    Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
    		[PMID: 17562366]
    MT2 EC50
    0.16 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B in MT2 cells
    Antiviral activity against wild type HIV1 3B in MT2 cells
    		[PMID: 18164198]
    MT2 EC50
    0.16 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
    Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
    		[PMID: 19179082]
    MT2 EC50
    0.18 μM
    Compound: N3ddThd
    Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells.
    Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells.
    		[PMID: 2153206]
    MT2 EC50
    0.209 μM
    Compound: AZT
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.223 μM
    Compound: AZT
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.249 μM
    Compound: AZT
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.302 μM
    Compound: AZT
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    47 nM
    Compound: AZT
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    		[PMID: 21745701]
    MT2 ED50
    0.07 μM
    Compound: AZT
    Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
    Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
    		[PMID: 7512142]
    MT2 ED50
    0.07 μM
    Compound: AZT
    Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells.
    Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells.
    		[PMID: 7684450]
    MT2 IC50
    0.006 μM
    Compound: AZT
    Inhibitory activity against the HIV-1-induced cytopathic effect in MT-2 cell line
    Inhibitory activity against the HIV-1-induced cytopathic effect in MT-2 cell line
    		[PMID: 7650678]
    MT2 IC50
    0.031 μM
    Compound: AZT
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    MT2 IC50
    0.047 μM
    Compound: AZT
    Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 20542430]
    MT2 IC50
    0.0493 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    		[PMID: 20728351]
    MT2 IC50
    0.05 μM
    Compound: AZT
    Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells
    Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells
    		[PMID: 18164198]
    MT2 IC50
    0.14 μg/mL
    Compound: AZT
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    		[PMID: 1738145]
    MT2 IC50
    0.16 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
    In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
    		[PMID: 1573638]
    MT2 IC50
    0.2 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
    In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
    		[PMID: 1573638]
    MT2 IC50
    0.22 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
    In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
    		[PMID: 1573638]
    MT2 IC50
    10 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
    In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
    		[PMID: 1573638]
    MT2 IC50
    119.84 μM
    Compound: AZT
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    131.71 μM
    Compound: AZT
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    1870 μM
    Compound: AZT
    Cytotoxicity against MT2 cells by XTT assay
    Cytotoxicity against MT2 cells by XTT assay
    		[PMID: 17935987]
    MT2 IC50
    1870 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells by XTT assay
    Cytotoxicity against human MT2 cells by XTT assay
    		[PMID: 20329730]
    MT2 IC50
    1872 μM
    Compound: AZT
    Cytotoxicity against human MT2 cells after 6 days by XTT assay
    Cytotoxicity against human MT2 cells after 6 days by XTT assay
    		[PMID: 20537902]
    MT2 IC50
    27 nM
    Compound: AZT
    Anti-HIV activity based on inhibition of HIV-1 induced cytopathogenicity in MT-2 cells.
    Anti-HIV activity based on inhibition of HIV-1 induced cytopathogenicity in MT-2 cells.
    		[PMID: 12699395]
    MT2 IC50
    31 μM
    Compound: AZT
    In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
    In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
    		[PMID: 1573638]
    MT2 IC50
    51.64 μM
    Compound: AZT
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    83.44 μM
    Compound: AZT
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    > 970 μM
    Compound: N3ddThd
    Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells.
    Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells.
    		[PMID: 2153206]
    MT4 CC50
    0.52 μg/mL
    Compound: AZT
    Cytotoxicity indicative of 50% survival concentration in virus-uninfected MT-4 cells.
    Cytotoxicity indicative of 50% survival concentration in virus-uninfected MT-4 cells.
    		[PMID: 12161143]
    MT4 CC50
    1.5 μg/mL
    Compound: AZT
    Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%.
    Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%.
    		[PMID: 9046339]
    MT4 CC50
    1.64 μg/mL
    Compound: AZT
    Cytotoxicity against MT-4 cells
    Cytotoxicity against MT-4 cells
    		[PMID: 14505657]
    MT4 CC50
    1.9 μg/mL
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 CC50
    100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability
    		[PMID: 22579418]
    MT4 CC50
    110 μM
    Compound: AZT
    Cytotoxic concentration against HIV-1 infected MT-4 cell lines
    Cytotoxic concentration against HIV-1 infected MT-4 cell lines
    		[PMID: 7837220]
    MT4 CC50
    113 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of MT-4 cells
    Cytotoxic concentration required to reduce the viability of MT-4 cells
    		10.1016/0960-894X(95)00208-B
    MT4 CC50
    113 μM
    Compound: AZT
    Compound was evaluated for the concentration required to reduce the viability of MT-4 cells.
    Compound was evaluated for the concentration required to reduce the viability of MT-4 cells.
    		10.1016/0960-894X(95)00585-H
    MT4 CC50
    12 μM
    Compound: AZT
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    		[PMID: 11459656]
    MT4 CC50
    12 μM
    Compound: AZT
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    		[PMID: 11958995]
    MT4 CC50
    140 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    150 μM
    Compound: AZT
    Ability to reduce 50% viability of MT-4 cells acutely infected with HIV-1 strain IIIB
    Ability to reduce 50% viability of MT-4 cells acutely infected with HIV-1 strain IIIB
    		[PMID: 8642557]
    MT4 CC50
    190 μM
    Compound: AZT
    Compound was tested for reduction of the viability of mock infected MT-4 cell in test-I
    Compound was tested for reduction of the viability of mock infected MT-4 cell in test-I
    		[PMID: 11128640]
    MT4 CC50
    2.01 μg/mL
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 19091580]
    MT4 CC50
    2.5813 μg/mL
    Compound: zidovudine
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 10425115]
    MT4 CC50
    20 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 1992136]
    MT4 CC50
    20 μM
    Compound: AZT
    Concentration of compound required to reduce MT-4 cells viability by 50%.
    Concentration of compound required to reduce MT-4 cells viability by 50%.
    		[PMID: 2016718]
    MT4 CC50
    20 μM
    Compound: AZT
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 2479745]
    MT4 CC50
    249 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23084898]
    MT4 CC50
    249 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    249 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    249.5 μM
    Compound: AZT, Azidothymidine
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 CC50
    249.5 μM
    Compound: AZT, Azidothymidine
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 CC50
    249.5 μM
    Compound: AZT, Azidothymidine
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 CC50
    27 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    2 μg/mL
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
    Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
    		[PMID: 27105027]
    MT4 CC50
    3.2 μM
    Compound: AZT
    Tested for 50% cytotoxic concentration based on the reduction of viability in mock-infected MT-4 cells
    Tested for 50% cytotoxic concentration based on the reduction of viability in mock-infected MT-4 cells
    		10.1016/0960-894X(96)00355-1
    MT4 CC50
    3.2 μM
    Compound: AZT
    Cytotoxic concentration based on the reduction of viability of mock-infected cells
    Cytotoxic concentration based on the reduction of viability of mock-infected cells
    		[PMID: 7540208]
    MT4 CC50
    3.7 μM
    Compound: AZT
    Cytotoxicity against MT4 cells by MTT method
    Cytotoxicity against MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 CC50
    3.7 μM
    Compound: AZT
    Cytotoxicity against MT4 cells by MTT assay
    Cytotoxicity against MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 CC50
    31 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    35.6 μM
    Compound: AZT
    Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.
    Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.
    		[PMID: 9767646]
    MT4 CC50
    35.6 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 17964796]
    MT4 CC50
    4.8 μM
    Compound: AzddThd
    Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50%
    		[PMID: 1697345]
    MT4 CC50
    42 μM
    Compound: AZT
    Conc. required to cause 50% death of uninfected MT-4 cells
    Conc. required to cause 50% death of uninfected MT-4 cells
    		[PMID: 11520210]
    MT4 CC50
    42 μM
    Compound: AZT
    Concentration required to cause 50% death of uninfected MT-4 cells (expressed in AZT equivalent)
    Concentration required to cause 50% death of uninfected MT-4 cells (expressed in AZT equivalent)
    		[PMID: 11881996]
    MT4 CC50
    50 μM
    Compound: AZT
    Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay
    		10.1007/s00044-010-9513-0
    MT4 CC50
    50 μM
    Compound: AZT
    Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay
    		10.1007/s00044-012-0342-1
    MT4 CC50
    50 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 24805780]
    MT4 CC50
    50 μM
    Compound: AZT
    Concentration required to cause 50% death of uninfected MT-4 cells
    Concentration required to cause 50% death of uninfected MT-4 cells
    		[PMID: 9925728]
    MT4 CC50
    51 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 38954919]
    MT4 CC50
    57 μM
    Compound: AZT
    Cytotoxic concentration against the mock infected MT-4 cells
    Cytotoxic concentration against the mock infected MT-4 cells
    		[PMID: 15658852]
    MT4 CC50
    6 μM
    Compound: 1
    cytotoxic activity in MT-4 cell line
    cytotoxic activity in MT-4 cell line
    		[PMID: 8478904]
    MT4 CC50
    6 μM
    Compound: 1
    Cytotoxic concentration against MT-4 cells (in vitro)
    Cytotoxic concentration against MT-4 cells (in vitro)
    		[PMID: 8648614]
    MT4 CC50
    6 μM
    Compound: AZT
    Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells
    Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells
    		[PMID: 7527463]
    MT4 CC50
    60 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 19282192]
    MT4 CC50
    6000 nM
    Compound: 1
    Cytotoxicity against human lymphocyte MT-4 cells
    Cytotoxicity against human lymphocyte MT-4 cells
    		10.1016/0960-894X(94)80009-X
    MT4 CC50
    61 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTS method
    Cytotoxicity against human MT4 cells by MTS method
    		[PMID: 19254848]
    MT4 CC50
    65.4 μg/mL
    Compound: AZT
    Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay
    Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay
    		[PMID: 21515046]
    MT4 CC50
    7.06 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35679690]
    MT4 CC50
    7.5 μM
    Compound: Azidothymidine
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 28314514]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Concentration required to reduce viability of mock-infected MT-4 cells
    Concentration required to reduce viability of mock-infected MT-4 cells
    		[PMID: 1469700]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Concentration to required to reduce viability of Mock infected MT-4 cells
    Concentration to required to reduce viability of Mock infected MT-4 cells
    		[PMID: 1469700]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.
    		[PMID: 1732552]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect
    		[PMID: 2016715]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%
    Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%
    		[PMID: 2016729]
    MT4 CC50
    7.8 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 7636846]
    MT4 CC50
    7.8 μM
    Compound: AZT
    The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain
    The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain
    		[PMID: 7636846]
    MT4 CC50
    7.8 μM
    Compound: AZT
    The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain
    The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain
    		[PMID: 7636846]
    MT4 CC50
    74 μM
    Compound: AZT
    Cytotoxicity against in human MT-4 after 5 days by MTT assay
    Cytotoxicity against in human MT-4 after 5 days by MTT assay
    		[PMID: 33316719]
    MT4 CC50
    75 μM
    Compound: AZT
    Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line
    Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line
    		[PMID: 14521418]
    MT4 CC50
    75 μM
    Compound: AZT
    Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
    		[PMID: 7562927]
    MT4 CC50
    77.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay
    		[PMID: 30703659]
    MT4 CC50
    9.3 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.
    		[PMID: 1995896]
    MT4 CC50
    93.55 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 20638854]
    MT4 CC50
    93.56 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 CC50
    < 20 μM
    Compound: AZT
    Compound was tested for reduction of the viability of mock infected MT-4 cell in test-II
    Compound was tested for reduction of the viability of mock infected MT-4 cell in test-II
    		[PMID: 11128640]
    MT4 CC50
    > 0.00748 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 28481112]
    MT4 CC50
    > 0.1 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
    		[PMID: 26756779]
    MT4 CC50
    > 0.37 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
    Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
    		[PMID: 31184480]
    MT4 CC50
    > 0.37 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
    Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
    		[PMID: 33214842]
    MT4 CC50
    > 0.4 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
    Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
    		[PMID: 30031972]
    MT4 CC50
    > 0.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
    		[PMID: 28682067]
    MT4 CC50
    > 1 μM
    Compound: AZT
    Tested for cytotoxic concentration in MT-4 cell culture
    Tested for cytotoxic concentration in MT-4 cell culture
    		[PMID: 11087582]
    MT4 CC50
    > 1 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 20112915]
    MT4 CC50
    > 100 μM
    Compound: 1, AZT
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    		[PMID: 10821705]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Tested in vitro against MT-4 cells using MTT assay
    Tested in vitro against MT-4 cells using MTT assay
    		[PMID: 11087576]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against MT-4 (human leukemia) cells.
    Cytotoxicity against MT-4 (human leukemia) cells.
    		[PMID: 11262088]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Concentration required to cause 50% death of uninfected MT-4 cells (expressed in AZT equivalent)
    Concentration required to cause 50% death of uninfected MT-4 cells (expressed in AZT equivalent)
    		[PMID: 11881996]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
    Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
    		[PMID: 12593658]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 17548498]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 19944610]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22277590]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 23916148]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 26094944]
    MT4 CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    > 100 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 18585917]
    MT4 CC50
    > 15 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31860304]
    MT4 CC50
    > 15 μM
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    		[PMID: 31767136]
    MT4 CC50
    > 18710 nM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    		[PMID: 22712652]
    MT4 CC50
    > 1 μg/mL
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22652226]
    MT4 CC50
    > 2 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 34583311]
    MT4 CC50
    > 2.5 μg/mL
    Compound: Zidovudine
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    		10.1007/s00044-011-9664-7
    MT4 CC50
    > 20 μM
    Compound: AZT
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		10.1016/S0960-894X(97)00340-5
    MT4 CC50
    > 20 μM
    Compound: AZT
    Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells (4 days)
    Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells (4 days)
    		[PMID: 7562935]
    MT4 CC50
    > 20 μM
    Compound: AZT
    Compound dose required to reduce the viability of mock-infected cells by 50%
    Compound dose required to reduce the viability of mock-infected cells by 50%
    		[PMID: 7650679]
    MT4 CC50
    > 20 μM
    Compound: AZT
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 8558522]
    MT4 CC50
    > 2000 nM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 29353724]
    MT4 CC50
    > 25 μM
    Compound: azidothymidine
    Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
    		[PMID: 24926807]
    MT4 CC50
    > 25 μM
    Compound: azidothymidine
    Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
    Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
    		[PMID: 25946116]
    MT4 CC50
    > 25 μg/mL
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 27214512]
    MT4 CC50
    > 25 μg/mL
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 27647368]
    MT4 CC50
    > 25 μg/mL
    Compound: Azidothymidine
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
    		[PMID: 26707844]
    MT4 CC50
    > 25 μg/mL
    Compound: DDN, AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 CC50
    > 25 μg/mL
    Compound: Zidovudine
    Cytotoxicity against Homo sapiens (human) MT4 cells
    Cytotoxicity against Homo sapiens (human) MT4 cells
    		10.1007/s00044-011-9662-9
    MT4 CC50
    > 25 μg/mL
    Compound: Zidovudine
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    		10.1007/s00044-011-9705-2
    MT4 CC50
    > 25 μg/mL
    Compound: Zidovudine
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
    		10.1007/s00044-011-9776-0
    MT4 CC50
    > 3.74 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay
    		[PMID: 30010341]
    MT4 CC50
    > 30595 nM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 24769348]
    MT4 CC50
    > 30595 nM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 28628334]
    MT4 CC50
    > 30595 nM
    Compound: AZT
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32883642]
    MT4 CC50
    > 37 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 2 days
    Cytotoxicity against human MT4 cells after 2 days
    		[PMID: 22978745]
    MT4 CC50
    > 50 μM
    Compound: AZT
    Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 32305183]
    MT4 CC50
    > 500 μM
    Compound: AZT
    The compound was tested for cytotoxic concentration required to reduce the viability of MT-4 cells
    The compound was tested for cytotoxic concentration required to reduce the viability of MT-4 cells
    		[PMID: 11858989]
    MT4 CC50
    > 7 μM
    Compound: Azidothymidine
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 28314598]
    MT4 CC50
    > 7.06 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 36577220]
    MT4 CC50
    > 7.1 μM
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay
    		[PMID: 36640458]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 26613134]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 28254696]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 28987601]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 29559197]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 29635166]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29670703]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 30721060]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 32631509]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 32977301]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33279288]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    		[PMID: 34090079]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    		[PMID: 35640327]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability
    		[PMID: 36442370]
    MT4 CC50
    > 7.48 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37393790]
    MT4 CC50
    > 7.48 μM
    Compound: AZT; zidovudine
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 CC50
    > 7.48 μM
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 33979774]
    MT4 CC50
    > 7.484 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 29152052]
    MT4 CC50
    > 7.49 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31434039]
    MT4 CC50
    > 7.49 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 38996652]
    MT4 CC50
    > 7.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 33340914]
    MT4 CC50
    > 7.5 μM
    Compound: AZT ; azidothymidine
    Cytotoxicity against mock-infected human MT4 cells
    Cytotoxicity against mock-infected human MT4 cells
    		[PMID: 27234889]
    MT4 CC50
    > 7480 nM
    Compound: AZT
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34890994]
    MT4 CC50
    > 749 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 37976805]
    MT4 CC50
    > 80 μM
    Compound: AZT
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)
    Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)
    		[PMID: 7523675]
    MT4 CC50
    > 80 μM
    Compound: AZT
    Dose required to reduce the viability of mock-infected cells by 50%
    Dose required to reduce the viability of mock-infected cells by 50%
    		[PMID: 9154967]
    MT4 CC50
    > 88.26 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 CC50
    > 93.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 24411122]
    MT4 CC50
    > 93.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 24794751]
    MT4 CC50
    > 93.5 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 CC50
    > 93.5489 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 CC50
    > 93.55 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 18267363]
    MT4 CC50
    > 93.55 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    		[PMID: 19628308]
    MT4 CC50
    > 93.55 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 23099090]
    MT4 CC50
    > 93.55 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 CC50
    > 93.55 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    		[PMID: 25537532]
    MT4 CC50
    > 93.55 μM
    Compound: AZT, Azidothymidine
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 CC50
    > 93.55 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    		10.1007/s00044-009-9220-x
    MT4 CC50
    > 93.55 μM
    Compound: AZT, azidothymidine
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    		[PMID: 21683601]
    MT4 CC50
    > 93.55 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 CC50
    > 93.55 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 18824350]
    MT4 CC50
    > 93.55 μM
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 CC50
    > 93.55 μM
    Compound: azidothymidine,AZT
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 19643613]
    MT4 CC50
    > 93.56 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 CC50
    > 93.6 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 CC50
    > 93.63 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 23159806]
    MT4 CC50
    > 93550 nM
    Compound: AZT
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 CC50
    > 94 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 25626145]
    MT4 CC50
    > 94 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 25707013]
    MT4 CC50
    > 94 μM
    Compound: AZT
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 CC50
    > 94 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 CC50
    > 99 μM
    Compound: Azidothymidine
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    		[PMID: 27112451]
    MT4 CC50
    >= 3.74 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells by cellTiterGlo assay
    Cytotoxicity against human MT4 cells by cellTiterGlo assay
    		[PMID: 26562066]
    MT4 CC50
    >= 46 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 CC50
    >= 46.44 μM
    Compound: Zidovudine
    Cytotoxicity against human MT4 cells measured by MTT assay
    Cytotoxicity against human MT4 cells measured by MTT assay
    		[PMID: 22037050]
    MT4 CC50
    >= 49.77 μM
    Compound: AZT, Azidothymidine
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 CC50
    >= 50 μM
    Compound: AZT, azidothymidine
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    0.0005 μg/mL
    Compound: AZT
    Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells.
    Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells.
    		[PMID: 12161143]
    MT4 EC50
    0.0005 μg/mL
    Compound: AZT
    50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-1.
    50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-1.
    		[PMID: 9046339]
    MT4 EC50
    0.0007 μM
    Compound: AZT
    Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.
    Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.
    		[PMID: 9767646]
    MT4 EC50
    0.0007 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay
    Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay
    		[PMID: 17964796]
    MT4 EC50
    0.0007 μg/mL
    Compound: AZT
    50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-2.
    50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-2.
    		[PMID: 9046339]
    MT4 EC50
    0.0008 μM
    Compound: AZT
    Antiviral activity against HIV1 in MT4 cells
    Antiviral activity against HIV1 in MT4 cells
    		[PMID: 17188402]
    MT4 EC50
    0.0008 μg/mL
    Compound: AZT
    Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 19091580]
    MT4 EC50
    0.00094 μg/mL
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT4 EC50
    0.0009 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9664-7
    MT4 EC50
    0.0009 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9776-0
    MT4 EC50
    0.0012 μg/mL
    Compound: AZT
    Compound was evaluated for its inhibitory effect on the replication of HIV-1(IIIB) in MT-4 cells
    Compound was evaluated for its inhibitory effect on the replication of HIV-1(IIIB) in MT-4 cells
    		[PMID: 14505657]
    MT4 EC50
    0.0012 μg/mL
    Compound: AZT
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21515046]
    MT4 EC50
    0.0015 μg/mL
    Compound: AZT
    Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 19091580]
    MT4 EC50
    0.0016 μM
    Compound: Zidovudine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 25682562]
    MT4 EC50
    0.0019 μM
    Compound: Zidovudine
    Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 25682562]
    MT4 EC50
    0.001 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 EC50
    0.002 μM
    Compound: 1
    Anti HIV-1 activity in human lymphocyte MT-4 cell line
    Anti HIV-1 activity in human lymphocyte MT-4 cell line
    		[PMID: 8478904]
    MT4 EC50
    0.002 μM
    Compound: 1
    Activity against HIV-1 in MT-4 cells (in vitro)
    Activity against HIV-1 in MT-4 cells (in vitro)
    		[PMID: 8648614]
    MT4 EC50
    0.002 μM
    Compound: AZT
    Tested for the inhibitory activity of HIV-1 infected MT-4 cells
    Tested for the inhibitory activity of HIV-1 infected MT-4 cells
    		[PMID: 7527463]
    MT4 EC50
    0.002 μM
    Compound: AZT (table 3)
    Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    		10.1016/0960-894X(96)00216-8
    MT4 EC50
    0.0022 μg/mL
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT4 EC50
    0.0028 μM
    Compound: AZT
    Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells
    Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells
    		[PMID: 1469700]
    MT4 EC50
    0.0028 μM
    Compound: AZT
    Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells
    Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells
    		[PMID: 2016715]
    MT4 EC50
    0.0028 μM
    Compound: AZT
    The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD
    The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD
    		[PMID: 7636846]
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
    		10.1007/s00044-011-9662-9
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
    		10.1007/s00044-011-9662-9
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9664-7
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9705-2
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9705-2
    MT4 EC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		10.1007/s00044-011-9776-0
    MT4 EC50
    0.003 μM
    Compound: 1
    Anti HIV-2 activity in human lymphocyte MT-4 cell line
    Anti HIV-2 activity in human lymphocyte MT-4 cell line
    		[PMID: 8478904]
    MT4 EC50
    0.003 μM
    Compound: 1
    Activity against HIV-2 in MT-4 cells (in vitro)
    Activity against HIV-2 in MT-4 cells (in vitro)
    		[PMID: 8648614]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    		[PMID: 1469700]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells
    Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells
    		[PMID: 2016715]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect
    Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect
    		[PMID: 2016729]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay
    Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay
    		[PMID: 7504733]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Tested for the inhibitory activity of HIV-2 infected MT-4 cells
    Tested for the inhibitory activity of HIV-2 infected MT-4 cells
    		[PMID: 7527463]
    MT4 EC50
    0.003 μM
    Compound: AZT
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.
    		[PMID: 7636846]
    MT4 EC50
    0.003 μM
    Compound: AzddThd
    Effective concentration achieving 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    Effective concentration achieving 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    		[PMID: 1697345]
    MT4 EC50
    0.0032 μg/mL
    Compound: AZT
    In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay
    In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay
    		10.1016/0960-894X(95)00395-A
    MT4 EC50
    0.0033 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.004 μM
    Compound: AZT
    Tested for 50% effective concentration based on the inhibition of HIV-I induced cytopathic effect in MT-4 cells
    Tested for 50% effective concentration based on the inhibition of HIV-I induced cytopathic effect in MT-4 cells
    		10.1016/0960-894X(96)00355-1
    MT4 EC50
    0.004 μM
    Compound: AZT
    Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50%
    Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50%
    		[PMID: 2016718]
    MT4 EC50
    0.004 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    		[PMID: 22652226]
    MT4 EC50
    0.004 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
    		[PMID: 26756779]
    MT4 EC50
    0.004 μM
    Compound: AZT
    Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells
    Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells
    		[PMID: 7540208]
    MT4 EC50
    0.004 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    0.004 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT4 EC50
    0.004 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.0045 μM
    Compound: AZT
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    		[PMID: 1695683]
    MT4 EC50
    0.0045 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    0.0048 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0049 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.005 μM
    Compound: AZT
    Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa)
    Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa)
    		[PMID: 10212126]
    MT4 EC50
    0.005 μM
    Compound: AZT
    Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD)
    Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD)
    		[PMID: 10212126]
    MT4 EC50
    0.005 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    		[PMID: 18267363]
    MT4 EC50
    0.005 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    		[PMID: 24794751]
    MT4 EC50
    0.005 μM
    Compound: AZT
    Effective dose to achieve 50% protection of MT-4 cells from acutely infected HIV-1 strain IIIB
    Effective dose to achieve 50% protection of MT-4 cells from acutely infected HIV-1 strain IIIB
    		[PMID: 8642557]
    MT4 EC50
    0.005 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.0052 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.0052 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0056 μM
    Compound: AZT
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.0057 μM
    Compound: AZT, Zidovudine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 EC50
    0.0059 μM
    Compound: AZT
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.006 μM
    Compound: AZT
    The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-2(ROD)
    The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-2(ROD)
    		[PMID: 11858989]
    MT4 EC50
    0.006 μM
    Compound: AZT
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    		[PMID: 1695683]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.
    Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.
    		[PMID: 1732552]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT
    Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT
    		[PMID: 18267363]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23159806]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23159806]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    		[PMID: 24794751]
    MT4 EC50
    0.006 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 EC50
    0.006 μM
    Compound: AZT ; azidothymidine
    Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    0.006 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    0.006 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.006 μM
    Compound: Zidovudine
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.006 μM
    Compound: Zidovudine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.006 μM
    Compound: azidothymidine
    Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
    Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
    		[PMID: 25946116]
    MT4 EC50
    0.0063 μM
    Compound: AZT
    Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.0064 μM
    Compound: AZT
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.0064 μM
    Compound: AZT
    The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-1(IIIB)
    The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-1(IIIB)
    		[PMID: 11858989]
    MT4 EC50
    0.0064 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.0066 μM
    Compound: AZT
    Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.0066 μM
    Compound: AZT
    Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25537532]
    MT4 EC50
    0.0067 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0067 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    		[PMID: 24794751]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25707013]
    MT4 EC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 EC50
    0.007 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    0.007 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    0.007 μM
    Compound: AZT; zidovudine
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 EC50
    0.007 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.007 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.007 μM
    Compound: Zidovudine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.0071 μM
    Compound: AZT
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25537532]
    MT4 EC50
    0.0071 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0071 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 EC50
    0.0071 μM
    Compound: azidothymidine
    Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
    Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
    		[PMID: 25946116]
    MT4 EC50
    0.0072 μM
    Compound: AZT, Zidovudine
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 EC50
    0.0074 μM
    Compound: AZT, Zidovudine
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 EC50
    0.0075 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 EC50
    0.0075 μM
    Compound: Zidovudine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22037050]
    MT4 EC50
    0.0075 μM
    Compound: Zidovudine
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22037050]
    MT4 EC50
    0.0076 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.007 μg/mL
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay
    Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23159806]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26613134]
    MT4 EC50
    0.008 μM
    Compound: AZT ; azidothymidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    0.008 μM
    Compound: Azidothymidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27112451]
    MT4 EC50
    0.0082 μM
    Compound: AZT; zidovudine
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 EC50
    0.0083 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0086 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 EC50
    0.009 μM
    Compound: AZT
    Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method
    Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method
    		[PMID: 19254848]
    MT4 EC50
    0.009 μM
    Compound: AZT
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.009 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    0.0099 μM
    Compound: AZT
    Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells
    Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells
    		[PMID: 14698189]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		10.1007/s00044-010-9513-0
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay
    		10.1007/s00044-012-0342-1
    MT4 EC50
    0.01 μM
    Compound: AZT
    Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    		10.1016/S0960-894X(97)00340-5
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25537532]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25626145]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25707013]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26613134]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Inhibition of HIV-1 (strain A17)-infected MT-4 cells
    Inhibition of HIV-1 (strain A17)-infected MT-4 cells
    		[PMID: 7504733]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days)
    Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days)
    		[PMID: 7523675]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Protection of MT-4 cells against the cytopathic effect of HIV-1 (4 days)
    Protection of MT-4 cells against the cytopathic effect of HIV-1 (4 days)
    		[PMID: 7562935]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity
    Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity
    		[PMID: 7650679]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells
    Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells
    		[PMID: 8558522]
    MT4 EC50
    0.01 μM
    Compound: AZT
    Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells
    Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells
    		[PMID: 9154967]
    MT4 EC50
    0.01 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    0.01 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    0.01 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 EC50
    0.011 μM
    Compound: AZT
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.011 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.011 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.012 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 EC50
    0.013 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 replication in human MT4 cells
    Antiviral activity against HIV1 NL4-3 replication in human MT4 cells
    		[PMID: 16942019]
    MT4 EC50
    0.013 μM
    Compound: AZT
    Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 EC50
    0.013 μM
    Compound: AZT
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
    		[PMID: 26094944]
    MT4 EC50
    0.013 μM
    Compound: AZT
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.013 μM
    Compound: Zidovudine
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22037050]
    MT4 EC50
    0.015 μM
    Compound: AZT
    Tested for anti-HIV -1 Activity in MT-4 cell culture
    Tested for anti-HIV -1 Activity in MT-4 cell culture
    		[PMID: 11087582]
    MT4 EC50
    0.015 μM
    Compound: AZT
    Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells
    Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells
    		[PMID: 12593658]
    MT4 EC50
    0.015 μM
    Compound: AZT
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine
    		[PMID: 26094944]
    MT4 EC50
    0.015 μM
    Compound: AZT, azidothymidine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 21683601]
    MT4 EC50
    0.015 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 infected human MT4 cells
    Antiviral activity against HIV1 infected human MT4 cells
    		[PMID: 18585917]
    MT4 EC50
    0.0151 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 19628308]
    MT4 EC50
    0.0151 μM
    Compound: AZT, azidothymidine
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    		10.1007/s00044-009-9220-x
    MT4 EC50
    0.0151 μM
    Compound: AZT, zidovudine
    Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity
    Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity
    		[PMID: 18824350]
    MT4 EC50
    0.0151 μM
    Compound: azidothymidine,AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    		[PMID: 19643613]
    MT4 EC50
    0.016 μM
    Compound: AZT
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    		[PMID: 1992136]
    MT4 EC50
    0.016 μM
    Compound: AZT
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    		[PMID: 2479745]
    MT4 EC50
    0.016 μM
    Compound: AZT ; azidothymidine
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    0.016 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 EC50
    0.017 μM
    Compound: AZT
    Effective concentration required to inhibit HIV-1 replication in MT-4 cell line
    Effective concentration required to inhibit HIV-1 replication in MT-4 cell line
    		[PMID: 14521418]
    MT4 EC50
    0.017 μM
    Compound: AZT
    Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
    		[PMID: 7562927]
    MT4 EC50
    0.017 μM
    Compound: AZT; zidovudine
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 EC50
    0.018 μM
    Compound: AZT
    Effective concentration against HIV-induced cytopathogenicity in MT-4 cells
    Effective concentration against HIV-induced cytopathogenicity in MT-4 cells
    		[PMID: 15658852]
    MT4 EC50
    0.018 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.018 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.018 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.019 μM
    Compound: AZT
    Antiviral activity against HIV1 FHR2 replication in MT4 cells
    Antiviral activity against HIV1 FHR2 replication in MT4 cells
    		[PMID: 16942019]
    MT4 EC50
    0.019 μM
    Compound: AZT
    Antiviral activity against HIV1 PI-R replication in human MT4 cells
    Antiviral activity against HIV1 PI-R replication in human MT4 cells
    		[PMID: 16942019]
    MT4 EC50
    0.01 μg/mL
    Compound: AZT
    Compound was evaluated for its inhibitory effect on the replication of HIV-2 (ROD) in MT-4 cells
    Compound was evaluated for its inhibitory effect on the replication of HIV-2 (ROD) in MT-4 cells
    		[PMID: 14505657]
    MT4 EC50
    0.02 μM
    Compound: 1, AZT
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    		[PMID: 10821705]
    MT4 EC50
    0.02 μM
    Compound: AZT
    Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI
    Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI
    		[PMID: 12852759]
    MT4 EC50
    0.02 μM
    Compound: AZT
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.02 μM
    Compound: AZT
    Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22277590]
    MT4 EC50
    0.02 μM
    Compound: AZT
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.02 μM
    Compound: AZT
    Inhibition of cytopathic effect of HIV-1 strain RF in MT-4 cell culture
    Inhibition of cytopathic effect of HIV-1 strain RF in MT-4 cell culture
    		[PMID: 8230098]
    MT4 EC50
    0.02 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.021 μM
    Compound: AZT
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.021 μM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    0.021 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT4 EC50
    0.022 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.022 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.022 μM
    Compound: Zidovudine
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.026 μM
    Compound: AZT
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.027 μM
    Compound: AZT
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.027 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay
    		[PMID: 20673723]
    MT4 EC50
    0.03 μM
    Compound: AZT
    Antiviral activity against AZT-resistant HIV1 ADP/141 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human MT4 cells
    Antiviral activity against AZT-resistant HIV1 ADP/141 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human MT4 cells
    		[PMID: 26613134]
    MT4 EC50
    0.032 μM
    Compound: AZT
    Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA
    Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA
    		[PMID: 26562066]
    MT4 EC50
    0.033 μM
    Compound: AZT
    Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay
    Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay
    		[PMID: 17548498]
    MT4 EC50
    0.035 μM
    Compound: AZT
    Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells
    Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells
    		10.1016/0960-894X(95)00208-B
    MT4 EC50
    0.038 μM
    Compound: AZT
    Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay
    Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay
    		[PMID: 11087576]
    MT4 EC50
    0.04 μM
    Compound: AZT
    Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells.
    Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells.
    		10.1016/0960-894X(95)00585-H
    MT4 EC50
    0.04 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 23916148]
    MT4 EC50
    0.04 μM
    Compound: AZT
    Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days)
    Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days)
    		[PMID: 7523675]
    MT4 EC50
    0.04 μM
    Compound: AZT
    Protection of MT-4 cells against the cytopathic effect of HIV-2 (8 days)
    Protection of MT-4 cells against the cytopathic effect of HIV-2 (8 days)
    		[PMID: 7562935]
    MT4 EC50
    0.05 μM
    Compound: AZT
    Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells
    Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells
    		[PMID: 9925728]
    MT4 EC50
    0.056 μM
    Compound: AZT
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.058 μM
    Compound: AZT
    Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity
    Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity
    		[PMID: 22579418]
    MT4 EC50
    0.067 μM
    Compound: AZT
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.085 μM
    Compound: AZT
    Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay
    Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay
    		[PMID: 7932526]
    MT4 EC50
    0.1 μM
    Compound: AZT
    Effective concentration against HIV-I RTMDR1 in MT-4 cells
    Effective concentration against HIV-I RTMDR1 in MT-4 cells
    		[PMID: 15267246]
    MT4 EC50
    0.1 μM
    Compound: AZT
    Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    0.12 μM
    Compound: AZT
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 26094944]
    MT4 EC50
    0.2 μM
    Compound: AZT
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.2 μM
    Compound: AZT
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.2 μM
    Compound: AZT
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.3 μM
    Compound: AZT
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    		[PMID: 11958995]
    MT4 EC50
    0.3 μM
    Compound: AZT
    The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain
    The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain
    		[PMID: 7636846]
    MT4 EC50
    0.6 μM
    Compound: AZT
    Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19282192]
    MT4 EC50
    1.6 nM
    Compound: AZT
    Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    10 nM
    Compound: AZT
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    11.7 nM
    Compound: AZT
    Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    12 nM
    Compound: AZT
    Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells
    Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells
    		[PMID: 11520210]
    MT4 EC50
    12 nM
    Compound: AZT
    Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent)
    Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent)
    		[PMID: 11881996]
    MT4 EC50
    15.6 nM
    Compound: AZT
    Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    16 nM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    16 nM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    2.5 nM
    Compound: 1
    In vitro inhibitory activity against replication of HIV-1 in human lymphocyte MT-4 cells
    In vitro inhibitory activity against replication of HIV-1 in human lymphocyte MT-4 cells
    		10.1016/0960-894X(94)80009-X
    MT4 EC50
    2.6 nM
    Compound: 1
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte MT-4 cells
    In vitro inhibitory activity against replication of HIV-2 in human lymphocyte MT-4 cells
    		10.1016/0960-894X(94)80009-X
    MT4 EC50
    20 μM
    Compound: AZT
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay
    		[PMID: 23375089]
    MT4 EC50
    20.6 nM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 EC50
    25 nM
    Compound: AZT
    Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent)
    Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent)
    		[PMID: 11881996]
    MT4 EC50
    2 ng/mL
    Compound: AZT
    Inhibitory activity toward HIV replication in MT-4 cells
    Inhibitory activity toward HIV replication in MT-4 cells
    		[PMID: 1323681]
    MT4 EC50
    3.7 nM
    Compound: AZT
    Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    3.8 nM
    Compound: AZT
    Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    3.8 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    33 nM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    4.8 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    48 nM
    Compound: AZT
    Inhibition of HIV-induced cytopathogenicity in MT-4 cell (ZIDOVUDINE control)
    Inhibition of HIV-induced cytopathogenicity in MT-4 cell (ZIDOVUDINE control)
    		[PMID: 11128640]
    MT4 EC50
    5.2 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    5.8 nM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    6 nM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    6 nM
    Compound: AZT, Azidothymidine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    6 μM
    Compound: AZT, azidothymidine
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    6 μM
    Compound: azidothymidine
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 25970561]
    MT4 EC50
    6.3 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    6.6 nM
    Compound: AZT
    Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    6.7 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    7.1 nM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25626145]
    MT4 EC50
    7.1 μM
    Compound: azidothymidine
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 25970561]
    MT4 EC50
    7.3 nM
    Compound: AZT
    Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    7.8 nM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    7.9 nM
    Compound: AZT
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay (ZIDOVUDINE control)
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay (ZIDOVUDINE control)
    		[PMID: 11459656]
    MT4 EC50
    > 7.48 μM
    Compound: AZT
    Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells
    Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells
    		[PMID: 26613134]
    MT4 EC50
    4.0 x 10-9 M
    Compound: AZT
    Tested for in vitro cytopathic effect of HIV for MT-4 cells
    Tested for in vitro cytopathic effect of HIV for MT-4 cells
    		[PMID: 7932583]
    MT4 ED50
    0.003 μM
    Compound: AZT
    Inhibitory activity against HIV-1 replication in MT-4 cells
    Inhibitory activity against HIV-1 replication in MT-4 cells
    		[PMID: 2754700]
    MT4 ED50
    0.003 μM
    Compound: AzddThd (AZT)
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    		[PMID: 2342078]
    MT4 ED50
    0.004 μM
    Compound: 1a
    Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.
    Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.
    		[PMID: 3172142]
    MT4 ED50
    0.004 μM
    Compound: 2
    Concentration required to affect a 50% reduction in the cytopathic effect of HIV for MT-4 cells
    Concentration required to affect a 50% reduction in the cytopathic effect of HIV for MT-4 cells
    		[PMID: 1527788]
    MT4 ED50
    0.004 μM
    Compound: AZT
    Cytopathogenicity against HIV-1 induced, replication in MT-4 cells was determined
    Cytopathogenicity against HIV-1 induced, replication in MT-4 cells was determined
    		[PMID: 2299647]
    MT4 ED50
    0.004 μM
    Compound: AZT
    Cytopathogenicity against HIV-2 induced replication in MT-4 cells was determined
    Cytopathogenicity against HIV-2 induced replication in MT-4 cells was determined
    		[PMID: 2299647]
    MT4 ED50
    0.006 μM
    Compound: AZT
    Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction
    Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction
    		[PMID: 3499515]
    MT4 ED50
    0.06 μM
    Compound: AZT
    Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50%
    Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50%
    		10.1016/S0960-894X(01)80332-2
    MT4 IC50
    0.0002 μg/mL
    Compound: zidovudine
    Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 10425115]
    MT4 IC50
    0.00094 μg/mL
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27647368]
    MT4 IC50
    0.00094 μg/mL
    Compound: DDN, AZT
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    0.0015 μM
    Compound: AZT
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.
    		[PMID: 1995896]
    MT4 IC50
    0.0017 μM
    Compound: AZT
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 IC50
    0.0022 μg/mL
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27647368]
    MT4 IC50
    0.0022 μg/mL
    Compound: DDN, AZT
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    0.002 μg/mL
    Compound: Zidovudine
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
    		[PMID: 27105027]
    MT4 IC50
    0.004 μM
    Compound: AZT
    Ability to block replication of HIV-1 virus in mock infected MT-4 cells
    Ability to block replication of HIV-1 virus in mock infected MT-4 cells
    		[PMID: 1956037]
    MT4 IC50
    0.0041 μM
    Compound: AZT
    Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
    		[PMID: 7877144]
    MT4 IC50
    0.005 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 20638854]
    MT4 IC50
    0.005 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 infected MT-4 cell lines
    Inhibitory concentration against HIV-1 infected MT-4 cell lines
    		[PMID: 7837220]
    MT4 IC50
    0.006 μM
    Compound: azidothymidine
    Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
    Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
    		[PMID: 24926807]
    MT4 IC50
    0.0066 μM
    Compound: AZT
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 IC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HIV-1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 23099090]
    MT4 IC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    		[PMID: 24411122]
    MT4 IC50
    0.007 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    		[PMID: 24411122]
    MT4 IC50
    0.0071 μM
    Compound: azidothymidine
    Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
    		[PMID: 24926807]
    MT4 IC50
    0.0077 μM
    Compound: AZT
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 IC50
    0.01 μM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay
    		[PMID: 19944610]
    MT4 IC50
    0.018 μM
    Compound: AZT
    Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay
    Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay
    		[PMID: 20112915]
    MT4 IC50
    0.02 μg/mL
    Compound: 4
    Inhibitory Effect against HIV-1 (IIIB) in CEM cells
    Inhibitory Effect against HIV-1 (IIIB) in CEM cells
    		[PMID: 7473592]
    MT4 IC50
    0.03 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA
    		[PMID: 22978745]
    MT4 IC50
    0.04 μM
    Compound: AZT
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    		[PMID: 15109677]
    MT4 IC50
    0.05 μM
    Compound: AZT
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay
    		[PMID: 18212100]
    MT4 IC50
    1.5 nM
    Compound: AZT
    Antiviral activity against HIV1 3B infected in MT4 cells
    Antiviral activity against HIV1 3B infected in MT4 cells
    		[PMID: 22268494]
    MT4 IC50
    100 μM
    Compound: AZT
    Concentration of compound required to reduce MT-4 cell viability by 50%
    Concentration of compound required to reduce MT-4 cell viability by 50%
    		[PMID: 10212126]
    MT4 IC50
    35.6 μM
    Compound: AZT
    In vitro inhibitory activity against uninfected T4 cells
    In vitro inhibitory activity against uninfected T4 cells
    		[PMID: 10956199]
    MT4 IC50
    53 μM
    Compound: AZT
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    		[PMID: 1695683]
    MT4 IC50
    57.28 μg/mL
    Compound: 4
    Concentration required to reduce the number of viable uninfected cells by 50%
    Concentration required to reduce the number of viable uninfected cells by 50%
    		[PMID: 7473592]
    MT4 IC50
    60 nM
    Compound: 1
    Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay
    Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay
    		[PMID: 1380561]
    MT4 IC50
    > 0.009 μM
    Compound: AZT
    Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 23099090]
    MT4 IC50
    > 37.4 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells after 4 days
    Cytotoxicity against human MT4 cells after 4 days
    		[PMID: 20673723]
    MT4 IC50
    > 37.5 μM
    Compound: AZT
    Inhibitory concentration against HIV-I RTMDR1 in MT-4 cells
    Inhibitory concentration against HIV-I RTMDR1 in MT-4 cells
    		[PMID: 15267246]
    MT4 IC50
    > 37.5 μM
    Compound: AZT
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 16942019]
    Macrophage CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against macrophages
    Cytotoxicity against macrophages
    		[PMID: 16279773]
    NCI-H460 IC50
    6.81 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    NHDF IC50
    14.41 μM
    Compound: 3; AZT
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    NHDF IC50
    14.41 μM
    Compound: AZT
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    		[PMID: 27501415]
    NIH3T3 IC50
    > 200 μM
    Compound: 13, AZT
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    PBL CC50
    12 μM
    Compound: AZT
    The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain
    The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain
    		[PMID: 7636846]
    PBL CC50
    26 μM
    Compound: AZT
    Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells.
    Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells.
    		[PMID: 1469700]
    PBL EC50
    0.0014 μM
    Compound: AZT
    Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells
    Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells
    		[PMID: 1469700]
    PBL EC50
    0.029 μM
    Compound: AZT
    Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay
    Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay
    		[PMID: 7932526]
    PBMC CC50
    1071 μM
    Compound: AZT
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31557609]
    PBMC CC50
    126 μM
    Compound: AZT
    Cytotoxicity against human PBMC by XTT assay
    Cytotoxicity against human PBMC by XTT assay
    		[PMID: 19581097]
    PBMC CC50
    126 μM
    Compound: AZT
    Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay
    Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay
    		[PMID: 32244098]
    PBMC CC50
    128 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 7 days by XTT assay
    Cytotoxicity against human PBMC after 7 days by XTT assay
    		[PMID: 22763201]
    PBMC CC50
    31.2 μg/mL
    Compound: AZT
    Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
    Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
    		[PMID: 21334901]
    PBMC CC50
    75 μM
    Compound: AZT
    Cytotoxicity against human PBMC by MTT assay
    Cytotoxicity against human PBMC by MTT assay
    		[PMID: 19944610]
    PBMC CC50
    > 1 μM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM
    Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM
    		[PMID: 16420027]
    PBMC CC50
    > 1 μM
    Compound: AZT
    Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM
    Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM
    		[PMID: 16420027]
    PBMC CC50
    > 1 μM
    Compound: AZT
    Cytotoxicity in human PBMC cells
    Cytotoxicity in human PBMC cells
    		[PMID: 27933957]
    PBMC CC50
    > 10 μM
    Compound: AZT
    Cytotoxicity against human PHA-PBMC cells by MTT assay
    Cytotoxicity against human PHA-PBMC cells by MTT assay
    		[PMID: 17548498]
    PBMC CC50
    > 10 μM
    Compound: AZT
    Cytotoxic concentration against PBMC cells
    Cytotoxic concentration against PBMC cells
    		[PMID: 7684450]
    PBMC CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 2 to 4 days by MTT assay
    Cytotoxicity against human PBMC after 2 to 4 days by MTT assay
    		[PMID: 19596885]
    PBMC CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 23623492]
    PBMC CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 25458500]
    PBMC CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    		[PMID: 26451771]
    PBMC CC50
    > 100 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay
    Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay
    		[PMID: 21376429]
    PBMC CC50
    > 1000 nM
    Compound: AZT
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 16698265]
    PBMC EC50
    0.0018 μM
    Compound: Zidovudine (AZT)
    Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells
    Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells
    		[PMID: 15916425]
    PBMC EC50
    0.0018 μM
    Compound: Zidovudine (AZT)
    Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells
    Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells
    		[PMID: 15916425]
    PBMC EC50
    0.0033 μM
    Compound: AZT
    Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay
    Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay
    		[PMID: 25701249]
    PBMC EC50
    0.004 μM
    Compound: AZT
    Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells
    Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells
    		[PMID: 15027854]
    PBMC EC50
    0.004 μM
    Compound: AZT
    Antiviral activity against HIV-1 strain LAI in PBM cells on day 6
    Antiviral activity against HIV-1 strain LAI in PBM cells on day 6
    		[PMID: 8057301]
    PBMC EC50
    0.004 μM
    Compound: AZT
    Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV
    Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV
    		[PMID: 8410975]
    PBMC EC50
    0.008 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.016 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.018 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.024 μM
    Compound: AZT
    Effective concentration of compound against HIV-1 89.6 strain in PBMC cells
    Effective concentration of compound against HIV-1 89.6 strain in PBMC cells
    		[PMID: 14698189]
    PBMC EC50
    0.034 μM
    Compound: AZT
    Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.05 μM
    Compound: AZT
    Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA
    Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA
    		[PMID: 19581097]
    PBMC IC50
    0.00021 mM
    Compound: AZT
    Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA
    Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA
    		10.1039/C4MD00003J
    PBMC IC50
    0.004 μM
    Compound: 4
    The compound was tested for anti HIV-activity (active) against PBM cell line
    The compound was tested for anti HIV-activity (active) against PBM cell line
    		[PMID: 10450963]
    PBMC IC50
    0.14 nM
    Compound: AZT
    Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM
    Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM
    		[PMID: 16420027]
    PBMC IC50
    0.18 nM
    Compound: AZT
    Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM
    Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM
    		[PMID: 16420027]
    PBMC IC50
    0.8291 mM
    Compound: AZT
    Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA
    Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA
    		10.1039/C4MD00003J
    PBMC IC50
    100 μM
    Compound: AZT
    Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
    Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
    		[PMID: 21700368]
    PBMC IC50
    > 100 μM
    Compound: 27, L-AZT
    Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
    Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
    		[PMID: 21700368]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay
    Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay
    		10.1007/s00044-011-9912-x
    PBMC IC50
    > 100 μM
    Compound: AZT
    Inhibitory activity was evaluated in human peripheral blood mononuclear (PBM) cells infected with Human immunodeficiency virus-1
    Inhibitory activity was evaluated in human peripheral blood mononuclear (PBM) cells infected with Human immunodeficiency virus-1
    		[PMID: 10197975]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 16509580]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 6 days
    Cytotoxicity against human PBMC after 6 days
    		[PMID: 17158051]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBM cells after 3 days by MTT assay
    Cytotoxicity against human PBM cells after 3 days by MTT assay
    		[PMID: 19153047]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 5 days
    Cytotoxicity against human PBMC after 5 days
    		[PMID: 19948402]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 5 days by trypan blue assay
    Cytotoxicity against human PBMC after 5 days by trypan blue assay
    		[PMID: 21371895]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
    Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
    		[PMID: 22014549]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 24091080]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    		[PMID: 25701249]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxic concentration against PBM cells was determined on day 6
    Cytotoxic concentration against PBM cells was determined on day 6
    		[PMID: 8057301]
    PBMC IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method
    Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method
    		[PMID: 9322359]
    PBMC IC50
    > 100 μM
    Compound: AZT, zidovudine
    Cytotoxicity against human PBMC
    Cytotoxicity against human PBMC
    		[PMID: 23085031]
    PBMC IC50
    > 100 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells
    Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells
    		[PMID: 15916425]
    PBMC IC50
    > 100 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells
    Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells
    		[PMID: 15916425]
    PC-3 IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    SK-MEL-28 IC50
    > 10 μM
    Compound: AZT
    The compound was tested in vitro for anticancer activity against SK-MEL-28 cells
    The compound was tested in vitro for anticancer activity against SK-MEL-28 cells
    		[PMID: 10072683]
    SK-MES-1 IC50
    > 100 μM
    Compound: AZT
    Tested in vitro for anticancer activity against SK-MES-1 cells
    Tested in vitro for anticancer activity against SK-MES-1 cells
    		[PMID: 10072683]
    SMMC-7721 IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    SUP-T1 IC50
    50 nM
    Compound: AZT
    Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay
    Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay
    		10.1016/0960-894X(95)00306-E
    SW-620 IC50
    39.11 μM
    Compound: AZT, Zidovudine
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 25440502]
    SW-620 IC50
    > 100 μM
    Compound: AZT
    Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
    		[PMID: 38964258]
    T-cell IC50
    0.01 μM
    Compound: AZT
    Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
    Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
    		[PMID: 1573638]
    T-cell line CC50
    66000 nM
    Compound: Zidovudine (AZT)
    In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay
    In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay
    		[PMID: 1712395]
    TZM CC50
    872 μM
    Compound: AZT
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31557609]
    TZM CC50
    > 0.374 μM
    Compound: AZT
    Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 32631509]
    TZM CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
    		[PMID: 33157478]
    TZM CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38954919]
    TZM CC50
    > 6300 nM
    Compound: AZT
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay
    		[PMID: 33340914]
    TZM IC50
    0.8 nM
    Compound: AZT
    Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy
    Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy
    		[PMID: 22858300]
    U-87MG ATCC IC50
    11.88 μM
    Compound: 3; AZT
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31400940]
    U-937 CC50
    110 μM
    Compound: AZT
    Cytotoxic concentration against HIV-1 infected U937 cell lines
    Cytotoxic concentration against HIV-1 infected U937 cell lines
    		[PMID: 7837220]
    U-937 EC50
    0.03 μM
    Compound: AZT
    Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay
    Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay
    		[PMID: 7932526]
    U-937 IC50
    0.04 μM
    Compound: AZT
    Inhibitory concentration against HIV-1 infected U937 cell lines
    Inhibitory concentration against HIV-1 infected U937 cell lines
    		[PMID: 7837220]
    U1 EC50
    25 μM
    Compound: AZT
    Antiviral activity was determined in chronically infected U1 cell line with HIV-1
    Antiviral activity was determined in chronically infected U1 cell line with HIV-1
    		[PMID: 11170632]
    Vero CC50
    126 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
    		[PMID: 18486994]
    Vero CC50
    39.5 μM
    Compound: AZT
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
    		[PMID: 26451771]
    Vero CC50
    53 μM
    Compound: AZT
    Cytotoxicity against African green monkey Vero cells
    Cytotoxicity against African green monkey Vero cells
    		[PMID: 23623492]
    Vero CC50
    56 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 25458500]
    Vero CC50
    > 100 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay
    		[PMID: 19596885]
    Vero EC50
    > 100 μM
    Compound: AZT
    Antiviral activity against Vero cells, infected with HSV-1
    Antiviral activity against Vero cells, infected with HSV-1
    		[PMID: 1720175]
    Vero EC50
    > 50 μM
    Compound: AZT
    Antiviral activity against HSV-1 strain F in Vero cells on day 2
    Antiviral activity against HSV-1 strain F in Vero cells on day 2
    		[PMID: 8057301]
    Vero IC50
    14.3 μM
    Compound: AZT
    Evaluated in vitro for their potential toxic effects against Vero cells
    Evaluated in vitro for their potential toxic effects against Vero cells
    		[PMID: 12540238]
    Vero IC50
    26 μM
    Compound: AZT
    The compound was tested for toxicity in Vero cells
    The compound was tested for toxicity in Vero cells
    		[PMID: 1720175]
    Vero IC50
    27.7 μM
    Compound: AZT
    Cytotoxicity in Vero cells
    Cytotoxicity in Vero cells
    		10.1016/0960-894X(95)00133-E
    Vero IC50
    27.7 μM
    Compound: AZT
    Compound was evaluated for cytotoxicity against Vero cells
    Compound was evaluated for cytotoxicity against Vero cells
    		10.1016/0960-894X(96)00171-0
    Vero IC50
    27.7 μM
    Compound: AZT
    Compound was evaluated for its cytotoxicity against vero cells.
    Compound was evaluated for its cytotoxicity against vero cells.
    		[PMID: 9873395]
    Vero IC50
    28 μM
    Compound: AZT
    Cytotoxic activity against HIV-1 in rapidly dividing vero cells
    Cytotoxic activity against HIV-1 in rapidly dividing vero cells
    		10.1016/0960-894X(95)00107-5
    Vero IC50
    28 μM
    Compound: AZT
    Cytotoxicity against Vero cells
    Cytotoxicity against Vero cells
    		[PMID: 12383014]
    Vero IC50
    28 μM
    Compound: AZT
    Cytotoxicity in vero cells.
    Cytotoxicity in vero cells.
    		[PMID: 1597854]
    Vero IC50
    28 μM
    Compound: AZT
    Cytotoxicity against uninfected PHA-stimulated vero cells was determined.
    Cytotoxicity against uninfected PHA-stimulated vero cells was determined.
    		[PMID: 8421287]
    Vero IC50
    28 μM
    Compound: AZT
    Cytotoxic effect against vero cells.
    Cytotoxic effect against vero cells.
    		[PMID: 8496934]
    Vero IC50
    28 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration against uninfected Vero cells
    Inhibitory concentration against uninfected Vero cells
    		[PMID: 15916425]
    Vero IC50
    28 μM
    Compound: Zidovudine (AZT)
    Inhibitory concentration against uninfected Vero cells
    Inhibitory concentration against uninfected Vero cells
    		[PMID: 15916425]
    Vero IC50
    29 μM
    Compound: AZT
    Compound was evaluated for the toxicity in rapidly dividing Vero cells (African Green monkeys kidney cells)
    Compound was evaluated for the toxicity in rapidly dividing Vero cells (African Green monkeys kidney cells)
    		10.1016/0960-894X(96)00210-7
    Vero IC50
    29 μM
    Compound: AZT
    Tested in vitro for cytotoxicity against Vero cells
    Tested in vitro for cytotoxicity against Vero cells
    		[PMID: 10072683]
    Vero IC50
    29 μM
    Compound: AZT
    Inhibitory activity was evaluated in Vero cells.
    Inhibitory activity was evaluated in Vero cells.
    		[PMID: 10197975]
    Vero IC50
    29 μM
    Compound: AZT
    In vitro cytotoxicity in vero cells.
    In vitro cytotoxicity in vero cells.
    		[PMID: 11689085]
    Vero IC50
    29 μM
    Compound: AZT
    Cytotoxicity against Vero cells was determined.
    Cytotoxicity against Vero cells was determined.
    		[PMID: 11882000]
    Vero IC50
    29 μM
    Compound: AZT
    Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated Vero cells
    Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated Vero cells
    		[PMID: 15027854]
    Vero IC50
    29 μM
    Compound: AZT
    Cytotoxicity was determined in Vero cells, relative to RVT
    Cytotoxicity was determined in Vero cells, relative to RVT
    		[PMID: 15081000]
    Vero IC50
    29 μM
    Compound: AZT
    Cytotoxicity against Vero cells
    Cytotoxicity against Vero cells
    		[PMID: 16509580]
    Vero IC50
    29 μM
    Compound: AZT
    Cytotoxic concentration against Vero cells was determined on day 3
    Cytotoxic concentration against Vero cells was determined on day 3
    		[PMID: 8057301]
    Vero IC50
    29 μM
    Compound: AZT
    Compound was evaluated for its toxicity by Calorimetric assay in vero cells
    Compound was evaluated for its toxicity by Calorimetric assay in vero cells
    		[PMID: 9357530]
    Vero IC50
    50 μM
    Compound: AZT
    Cytotoxicity against Vero cells after 3 days
    Cytotoxicity against Vero cells after 3 days
    		[PMID: 17158051]
    Vero IC50
    50.6 μM
    Compound: AZT
    Cytotoxicity against Vero cells
    Cytotoxicity against Vero cells
    		[PMID: 17085053]
    Vero IC50
    50.6 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    		[PMID: 19153047]
    Vero IC50
    50.6 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 5 days
    Cytotoxicity against african green monkey Vero cells after 5 days
    		[PMID: 19948402]
    Vero IC50
    50.6 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
    		[PMID: 21700368]
    Vero IC50
    56 μM
    Compound: AZT
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay
    		10.1007/s00044-011-9912-x
    Vero IC50
    56 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis
    		[PMID: 22014549]
    Vero IC50
    56 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 24091080]
    Vero IC50
    56 μM
    Compound: AZT
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
    		[PMID: 25701249]
    Vero IC50
    56 μM
    Compound: AZT, zidovudine
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 23085031]
    Vero IC50
    > 100 μM
    Compound: 27, L-AZT
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
    Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
    		[PMID: 21700368]
    Vero IC50
    > 100 μM
    Compound: AZT
    Inhibition of cell growth in vero cells
    Inhibition of cell growth in vero cells
    		[PMID: 8410975]
    Vero IC50
    > 100 μM
    Compound: AZT
    Cytotoxicity was determined in the vero cells infected with HIV-I
    Cytotoxicity was determined in the vero cells infected with HIV-I
    		[PMID: 8423591]
    WI-38 CC50
    > 100 μM
    Compound: Azidothymidine
    Cytotoxicity against human WI38 cells by neutral red assay
    Cytotoxicity against human WI38 cells by neutral red assay
    		[PMID: 18285481]
    WI-38 EC50
    > 100 μM
    Compound: Azidothymidine
    Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
    Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
    		[PMID: 18285481]
    In Vitro

    Zidovudine inhibits SVG, Primary human fetal astrocytes (PFA), peripheral blood mononuclear cells (PBMC), and monocyte-derived macrophages (MDM) with EC50 of 17, 1311, 8, and 5 nM, respectively. Zidovudine inhibits SVG, PFA, PBMC, and MDM with EC90 of 0.205 μM, 44.157 μM, 0.481 μM, and 0.219 μM, respectively[1]. The Cas9-mediated ablation of CXCR4 demonstrated high specificity and negligible off-target effects without affecting cell division and propagation[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Zidovudine Related Antibodies
    In Vivo

    Intravitrous injection of the NRTIs Lamivudine (3TC), Zidovudine (AZT), or Abacavir (ABC) suppresses the laser-induced choroidal neovascularization (CNV) in wild-type mice compared to PBS vehicle. The mean level of VEGF-A in the RPE/choroid, which peaks on day 3 after laser injury, is significantly reduced in 3TC-, AZT- and ABC-treated eyes compared with control eyes in wild-type mice, but not inP2rx7-/- mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    267.24

    Formula

    C10H13N5O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC[C@@H]1[C@@H](N=[N+]=[N-])C[C@H](N2C(NC(C(C)=C2)=O)=O)O1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (374.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 16.67 mg/mL (62.38 mM; ultrasonic and warming and heat to 60°C)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.7420 mL 18.7098 mL 37.4195 mL
    5 mM 0.7484 mL 3.7420 mL 7.4839 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 20 mg/mL (74.84 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.97%

    SDS (480 KB)

    COA (250 KB) RP-HPLC (206 KB) MS (73 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    Assays are performed in all cell types in the presence of titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000 PBMC, or 50,000 MDM cells/well are seeded into triplicate wells of 96-well plates. Twenty-four hours later, the culture medium is removed and replaced with medium containing the ARV or DMSO (0.5% vol/vol), and equivalent TCID50 infectious units of luciferase reporter virus are added to the cells. After a 16 h incubation at 37°C, the initial viral inoculum is removed and replaced with culture medium containing the same antiretroviral drug (ARV) or DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the medium is aspirated, the cells are lysed and HIV-1 infection measured using the Luciferase Assay System. Luminescence is measured using a FLUOStar Optima microplate reader. Inhibition curves and the 50% (EC50) and 90% (EC90) effective concentrations are determined by nonlinear regression analysis, using GraphPad Prism software[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3]

    Mice[3]
    C57BL/6J (wild-type) and P2rx7-/- mice are used. The Nlrp3-/- mice are used. The NRTIs 3TC, AZT, and ABC or the P2X7 antagonist A438079 hydrochloride are dissolved in PBS. For CNV, each group of mice is injected once with 1 μL of NRTIs (3TC, 125 ng/μL; ABC, 183 ng/μL; AZT, 146 ng/μL), 1 μL of A438079 hydrochloride (3, 30, or 300 ng/μL), or the same volume of vehicle (PBS) into the vitreous humor using a 33-gauge needle immediately after laser injury. Another group of mice is injected with 3TC (125 ng) in combination with an anti-mouse VEGF polyclonal antibody (10 ng). Goat whole IgG (10 ng) is used as a biological control for the anti-mouse VEGF antibody.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 3.7420 mL 18.7098 mL 37.4195 mL 93.5489 mL
    5 mM 0.7484 mL 3.7420 mL 7.4839 mL 18.7098 mL
    10 mM 0.3742 mL 1.8710 mL 3.7420 mL 9.3549 mL
    15 mM 0.2495 mL 1.2473 mL 2.4946 mL 6.2366 mL
    20 mM 0.1871 mL 0.9355 mL 1.8710 mL 4.6774 mL
    25 mM 0.1497 mL 0.7484 mL 1.4968 mL 3.7420 mL
    30 mM 0.1247 mL 0.6237 mL 1.2473 mL 3.1183 mL
    40 mM 0.0935 mL 0.4677 mL 0.9355 mL 2.3387 mL
    50 mM 0.0748 mL 0.3742 mL 0.7484 mL 1.8710 mL
    60 mM 0.0624 mL 0.3118 mL 0.6237 mL 1.5591 mL
    DMSO 80 mM 0.0468 mL 0.2339 mL 0.4677 mL 1.1694 mL
    100 mM 0.0374 mL 0.1871 mL 0.3742 mL 0.9355 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Zidovudine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Zidovudine30516-87-1Azidothymidine AZT ZDVHIVHuman immunodeficiency virusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Zidovudine
    Cat. No.:
    HY-17413
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.